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SUMMARY 
The pathogenesis of neurodegenerative diseases prior to the onset of 
symptoms is generally not clear. The present study has employed a mouse model 
with a lack of the low-molecular weight neurofilament subunit (NFL−/−), in 
which formation of protein aggregates occurs in neurons, to investigate glial 
cellular reactions in the lumbar cord segments of NFL−/− mice at ages from 1 to 6 
months. Age-matched C57BL/6 mice serve as the control. Apparent neurofilament 
positive aggregates in the cytoplasm of motoneurons have been observed in the 
spinal cord of NFL−/− mice. However, there were no noticeable changes in 
microglial numbers and GFAP staining of astrocytes. Unexpectedly, a 
downregulation in expression of α-subunit (CD11b) of complement receptor type 
3 (CR3) was detected in the spinal cord of NFL−/− mice, while there was no 
obvious difference in the CD11b staining intensity of macrophages from the liver 
and spleen between NFL−/− and C57BL/6 mice. In addition, retardation in 
morphological transformation from resting ramified to amoeboid microglia in 
response to sciatic nerve injury, differential expressions of some cytokines in the 
lumbar cord segments and induction of Iba-1 (ionized calcium-binding adaptor 
molecule-1) expression in microglia were observed in NFL−/− mice. The current 
results suggest not only the existence of an inhibitory niche for CD11b expression 
in microglia in the lumbar cord segments of NFL−/− mice but also differential 
microglial reactions between earlier and later stages of neuropathogenesis. 
Although the real cause for such inhibition is still unknown, this effect might play 
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a particular role in the survival of the abnormal protein aggregate-bearing 
motoneurons in the early development stage of neurodegeneration in the NFL−/− 
mice. 
Since other report has indicated that CD18 (β subunit of CR3) may not be 
responsible for fulfilling some microglial functions, the current study focused on 
CD11b only. In order to understand the meaning of the downregulation of CD11b 
expression in the earlier age of the NFL-/- mice, the transient siRNA transfection 
approach has been employed to specifically knockdown CD11b gene expression 
in BV-2 microglial cells and explore the role of CD11b in microglial activities and 
its cellular signalling mechanism induced by LPS. The BV-2 cells transfected with 
scrambled siRNA served as negative control. In an optimized condition, 
Real-Time PCR showed that there was around 88% and 82% decrease in CD11b 
mRNA expression in BV-2 cells transfected with CD11b siRNA at 48 and 72 hour 
post-transfection. Upon LPS stimulation, remarkable increases in NO generation 
and phagocytosis in normal BV-2 and the negative control cells were significantly 
reduced in CD11b siRNA transfected BV-2 cells. In addition, marked 
phosphorylation of ERK, JNK and P38 proteins and increases in IL-1β mRNA 
observed in normal BV-2 and the negative control cells were also significantly 
inhibited in CD11b knockdown cells. The conditioned medium from 
LPS-stimulated CD11b-knockdown BV-2 cells was found to be obviously less 
toxic to NSC-34 neurons than that from the controls. The inhibition of CD11b by 
siRNA may reduce microglial activation via the MAPkinase pathway. The 
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downregulation in CD11b expression may ameliorate the inflammation in 
neurodegenerative diseases, suggesting that the inhibitory environment in the 
earlier neuropathogenesis of neurodegenerative diseases might be neuroprotective. 
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1. Adult neurodegenerative diseases 
On 4th November 1906, Alois Alzheimer gave his first lecture on a patient 
with “a peculiar disorder of the cerebral cortex”. The late Auguste D. had suffered 
from dementia during the last years of her life, and in her brain Alzheimer had 
discovered protein plaques, neurofibrillary tangles and atherosclerotic changes. 
These features came to define what is now known as Alzheimer’s disease. 
Since then, we have learned much about a wide variety of 
neurodegenerative disorders, and there seem to be some remarkable parallels 
between them. It is clear that plaques and other atypical protein assemblies, 
massive neuronal death, marked microglial activation, proteasome dysfunction, 
mutations in mitochondria and oxidative stress all contribute to these diseases. 
Although the significance of these features is still hotly debated, the controversial 
reports of recovery of degenerating neurons following experimental therapies and 
the failure of many clinical trials (Thatte and Dahanukar, 1997) have given rise to 
crucial issues for therapeutic strategy: What would be the crucial therapeutic 
intervention points in neuropathogenic pathways and when would be the best time 
to deliver the treatment? An understanding of early pathological changes before 
any clinical symptom, such as abnormal protein aggregates in neuronal cells and 
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1.1 Protein aggregates and neurodegenerative diseases 
The correlation between neurodegenerative disease and protein aggregates 
in the brain has long been recognized, but a causal relationship has not been 
clearlly established, in part because a discrete pathogenic aggregate has not been 
identified. Protein aggregation of some types is now known to be a characteristic 
feature of most adult neurodegenerative diseases. However, the fibrillar deposits 
that are found in postmortem diseased brains, such as the amyloid plaques noted 
by Alzheimer, the Lewy bodies of Parkinson’s disease (PD) and related diseases, 
the ubiquitin positive aggregates in ALS and the nuclear inclusions of 
Huntington’s Disease (HD), can be present in the brains of asymptomatic 
individuals and do not correlate to the severity of disease at time of death. 
The possibility that protein aggregation causes neuronal dysfunction, cell 
death and neurodegeneration has returned to centre stage with the discovery that a 
gene linked to autosomal dominant familial Alzheimer’s disease (AD)  encodes a 
precursor (amyloid precursor protein, APP) of the amyloid-β protein (Aβ) (Goate 
et al., 1991). Aβ is a 4-kDa peptide that comprises the least soluble, fibrillar 
component of AD amyloid plaques (Glenner and Wong, 1984; Masters et al., 
1985) . During the past decade, a working hypothesis has been developed 
implicating protein aggregation as the trigger of the cascade of events that result 
in neurodegenerative diseases (Hardy and Selkoe, 2002). The model, known as the 
‘amyloid hypothesis’, has evolved with the understanding of the process of protein 
aggregation. In recent years, the hypothesis has been generalized as it has become 
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apparent that most neurodegenerative diseases are characterized by protein 
aggregates, albeit of varying composition. 
Neurodegeneration and the expression levels of certain disease-associated 
proteins are clearly related. For example, triplication (Singleton et al., 2003) or 
duplication (Chartier-Harlin et al., 2004) of the α-synuclein gene causes PD, and 
overexpression to a lesser extent due to a promoter polymorphism increases an 
individual’s risk of PD (Maraganore et al., 2006). This dependence is consistent 
with aggregation being important for the diseases. Interruption in normal 
cytoskeleton elements could also lead to protein aggregation in neurons. Obvious 
decreases in NFL expression have been reported in various types of 
neurodegenerative diseases, such as AD, PD, and ALS (McLachlan et al., 1988; 
Clark et al., 1989; Hill et al., 1993; Kittur et al., 1994; Wong et al., 2000; Menzies 
et al., 2002; Singleton et al., 2003; Maraganore et al., 2006), and in normal aging 
(Parhad et al., 1995; Kuchel et al., 1996).  
Although progressive neuronal loss is a hallmark of neurodegenerative 
disorders, some neurological impairment may lead to dysfunction rather than loss 
of neurons. Abnormal protein assemblies seem to trigger vicious cycles of 
aberrant neuronal activity and compensatory alterations in neurotransmitter 
receptors and related signalling pathways that lead to synaptic deficits, 
disintegration of neural networks, and, ultimately, failure of neurological functions. 
At least in animal models, some pathogenic cascades can be prevented or reversed, 
interestingly without obvious effects on neuronal numbers, by removing abnormal 
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proteins or pharmacologically modulating neuronal activities. Enhancing neuronal 
plasticity might help the remaining neural circuits to compensate for lost or 
broken circuits and improve overall network performance and neurological 
functions. In connection with this, the inflammation or immune reaction, in which 
microglia play a key role, in the neurodegenerative diseases should be a potential 
pharmaceutical target. 
1.2 Microglia and neurodegenerative diseases 
The involvement of microglial activation in the pathogenesis of several 
neurodegenerative diseases was initially postulated based on the postmortem 
analysis of the brains of patients with AD and PD. For instance, reactive microglia 
were found to colocalize with neuritic plaques in the cortical region of AD brains 
(Rogers et al., 1988). In PD brains, large numbers of human leukocyte antigen 
(HLA-DR)-positive reactive microglia were found in the substantia nigra, a region 
in which the degeneration of dopaminergic neurons was most prominent (McGeer 
et al., 1988). In addition to AD and PD, results from both in vivo and in vitro 
studies have since established an association of microglial activation with the 
pathogenesis of human immunodeficiency virus (HIV) acquired 
immunodeficiency syndrome dementia complex, ALS, multiple sclerosis, and 
prion-related diseases ( Dickson et al., 1993; Raine, 1994; Brown, 2001). 
1.2.1 Aging 
Many neurodegenerative diseases increase in prevalence with age. Normal 
aging in the human brain was accompanied by increasing numbers of activated 
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interleukin 1 (IL-1)-expressing microglia (Conde and Streit, 2006) and enlarged 
phagocytic microglial subtypes (Sheng et al., 1998). Analysis of rat cortical 
sections using the electron microscope at  24 and 27 months (which is equivalent 
to old age in humans) revealed a progressive increase in microglial activation with 
age (Vaughan and Peters, 1974)), and the spinal cord seemed to be similarly 
affected (Stuesse et al., 2000). Microglia from aged rat brains showed an increase 
in expressions of microglial protein markers OX42 and OX6 (Rozovsky et al., 
1998). In fact, several reports have proposed that the age-associated 
transformation of microglia could be a reflection of a chronic lifelong 
accumulation of minor insults leading to increased risk of neurodegenerative 
diseases, such as Alzheimer's disease (Blasko et al., 2004; Sheng et al., 1998). So, 
although the precise mechanisms are still unclear, microglial activation might 
contribute to an enhanced inflammatory response in the aging brain. 
1.2.2 Alzheimer's disease. 
Alzheimer's disease is the leading cause of dementia in the elderly and has 
been shown to be associated with the toxic effects of microglial activation 
(McGeer et al., 1987; Rogers et al., 1988; Yankner, 1989). Neural damage begins 
in the temporal and parietal lobes of the cerebral cortex and progresses over time 
to the hippocampus and amygdala (Braak and Braak, 1994) and microglial 
activation increases throughout disease progression (Xiang et al., 2006). Amyloid 
protein not only has direct toxicity to neurons (Yankner, 1989; Yankner et al., 
1990), but also can potentiate neuronal damage by microglial activation (Combs et 
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al., 2000; Qin et al., 2002). In fact, microglial overactivation is an early 
pathogenic event in patients with Alzheimer's disease (Cagnin et al., 2001). Even 
before the development of symptoms, activated microglia have been found to 
cluster at the sites of aggregated amyloid protein and penetrated the neuritic 
plaques (McGeer et al., 1987; Veerhuis et al., 1999). Amyloid protein is 
pro-inflammatory and is able to stimulate microglia to release neurotoxic factors 
such as NO (Ii et al., 1996), TNF-α (Dheen et al., 2005) and superoxide (Qin et al., 
2002). So, amyloid protein could recruit and activate microglia (Meda et al., 1995; 
Sasaki et al., 1997), indicating a crucial role for microglia in Alzheimer's disease 
progression (Griffin et al., 1998). 
1.2.3 Parkinson's disease. 
PD is characterized by a progressive and selective destruction of the 
nigrostriatal dopaminergic system that is important in the regulation of body 
movements. Numerous activated microglia are present in the vicinity of 
degenerating neurons in the substantia nigra of patients with PD and of those with 
other Parkinsonian syndromes (McGeer et al., 1988; Imamura et al., 2003;). The 
detection of elevated levels of proinflammatory cytokines and evidence of 
oxidative stress-mediated damage in postmortem PD brains have also provided 
strong supports to the notion of microglial involvement in the degenerative 
process.  
1.2.4 Other neurological disorders.  
Microglia have been linked to pathology and disease progression in other 
INTRODUCTION                                                    8
neurodegenerative disorders, including prion diseases (Combrinck et al., 2002; 
Perry et al., 2002), multiple sclerosis (Takeuchi et al., 2002; Kutzelnigg et al., 
2005), ALS (McGeer and McGeer, 2002; Solomon et al., 2006), Huntington's 
disease (Singhrao et al., 1999; Sapp et al., 2001) and Pick's disease (Paulus et al., 
1993; Schofield et al., 2003).  
In general, microglia play a critical role as resident immunocompetent and 
phagocytic cells within the CNS. Activation is associated with increased 
production of potentially cytotoxic molecules, including reactive oxygen species 
(ROS), NO, proteases and pro-inflammatory cytokines, such as IL-1β, TNF-α, and 
IL-6, together with induction of phagocytosis (Streit et al., 1999). Given these 
properties, there is little doubt that activated microglia can inflict significant 
damage on neighboring cells. However, their role is complex and microglia can be 
either neuroprotective or neurotoxic. The final outcome is likely to depend on the 
time and intensity of microglial reaction, the type of stimulation, and other local 
factors, including cross-talk with neighboring neuronal cells (Minghetti and Levi, 
1998; Li et al., 2007). But there is lack of information on microglial behaviors in 
earlier pathological development of neurodegenerative diseases. Further details on 
microglial reaction and its possible roles will be discussed in the later section. 
1.3 Astrocytes and neurodegenerative diseases 
Decades of pathological and physiological studies have focused on 
neuronal abnormalities and microglial activities in these disorders, but it is 
becoming increasingly evident that the astrocyte is also an important player in the 
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diseases. Astrocytic dysfunction may lead to neurodegenerative diseases in many 
ways: (a) Impairment of glutamate transporters may lead to increased synaptic 
glutamate and excitotoxicity (Maragakis and Rothstein, 2004); (b) Amyloid-β 
could potentially induce ATP secretion from astrocytes and interact with gap 
junctions to alter calcium signaling and glial communication (Haughey and 
Mattson, 2003); (c) Upregulation of glial fibrillary acidic protein (GFAP) is a 
consistent pathological feature in neurodegenerative diseases, but the significance 
of this observation has not been fully understood (Pekny, 2001). In addition, 
neurons surrounded by mutant astrocytes developed protein aggregates and axonal 
pathology, and were more susceptible to cell death in several neurodegenerative 
disease models, including ALS, AD and Huntington’s disease (Clement et al., 
2003; Forman et al., 2005; Shin et al., 2005). 
1.3.1 Alzheimer’s disease 
In the tissues from individuals with AD, activated astrocytes were closely 
associated with amyloid plaques in the molecular layer of the cerebral cortex 
(Wisniewski and Wegiel, 1991). Astrocytes might be activated by human 
amyloid-β (Aβ) (DeWitt et al., 1998), indicating a correlation between this protein 
and subsequent alterations in astrocytic function. Astrocytes also accumulate 
neuron-derived amyloid material resulting from local neurodegeneration. Once 
substantial accumulation of this debris occurs, the astrocytes themselves might 
undergo cell death, resulting in the formation of GFAP+ amyloid plaques (Nagele 
et al., 2004). 
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1.3.2 Parkinson’s disease 
Increases in the GFAP expression and number of astrocytes have been 
observed in PD (Forno et al., 1992). The correlation between PD and astrocytes 
has also been shown in many other studies. Seen from pathological examinations, 
increase in glutathione-peroxidase-containing cells was inversely correlated with 
the severity of dopaminergic cell loss in the respective cell groups in patients with 
PD. The quantity of glutathione-peroxidase-containing cells, therefore, might be 
critical for a protective effect against oxidative stress (Damier et al., 1993). 
Conversely, the presence of synuclein-positive astrocytes in pathological samples 
has been correlated with nigral neuronal cell death (Wakabayashi et al., 2000).  
1.3.3 Other neurodegenerative diseases 
In both human tissues and transgenic models of ALS, there is abundant 
evidence that astroglial abnormalities and physiological dysfunction precede 
clinical diseases. These changes include reactive astrocytosis that could be seen 
many months before motor neuron degeneration (Bruijn et al., 1997) and loss of 
glutamate transport and GLT1 protein expression before the onset of a clinical 
disease or overt motor neuron degeneration (Howland et al., 2002). Astrocytosis 
has also been observed in affected regions of the brain of patients with HD. The 
huntingtin protein co-localizes with these reactive astrocytes in specific regions 
(Singhrao et al., 1998). Glutamate excitotoxicity in HD has been hypothesized to 
result from the failure of astrocytic functions that require cell–cell coupling to 
maintain their network and contribute to metabolic homeostasis. Alterations in gap 
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junction expression or uncoupling of gap junctions between astrocytes would 
cause them to lose their ability to maintain a proper neuronal environment. 
1.4 Importance of early disease detection 
Recent studies have demonstrated that these disorders are characterized by 
a presymptomatic phase, likely lasting years, during which neuronal degeneration 
may occur before appearance of clinical symptoms. As the preclinical period of 
neurodegenerative diseases would be an opportunity for preventive therapy to stop 
or reverse pathogenesis, the challenges presented are: a). How can an individual 
be identified during this preclinical period? b).What could be the therapeutic 
targets at this stage? Therefore, a major goal of clinical research is to improve 
early detection of these diseases by developing tools to detect early signs of the 
neurodegeneration and, in order to introduce early therapeutic intervention, 
another goal is to understand more about the pathogenesis in the earlier 
pathological development stage. 
Early detection of neurodegenerative disorders may be crucial to enable us 
to understand and treat these disorders more effectively and to prevent or delay 
their further neuropathogenesis. The tools to assess early (and ideally preclinical) 
diseases are developing rapidly in tandem with improved understanding of the 
underlying molecular pathobiology of these disorders. Early disease detection 
depends on combining genetic biomarkers to identify at risk individuals with 
evidence of developing phenotype based on imaging, clinical, or biochemical 
measures. The understanding of early pathogenesis could in turn provide some 
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information on creating new biomarkers for earlier detection. 
It is understandable that it is very difficult to study early neuropathological 
development in the human. However, the transgenic animals could provide the 
possibility to investigate neuropathological development in early preclinical stage. 
In this study, the transgenic mouse with formation of protein aggregation in 
neurons will be adopted. 
1.5 NFL-/- mice 
NF, the major intermediate filament (IF) protein of adult neurons, is 
formed from the heteropolymerization of three subunit proteins with molecular 
weights of 68 kDa (NFL), 160 kDa (NFM), and 200 kDa (NFH) (Strong, 1999). 
Although the individual NF subunits co-assemble as obligate heteropolymers in 
vitro (Ching and Liem, 1993; Lee et al., 1993;Giasson et al., 1996; Leung and 
Liem, 1996) , it is the initial formation of NFL polymers that is integral to this 
process, with filament assembly also proceeding by NFL/NFM or NFL/NFH 
assembly intermediates (Giasson et al., 1996; Streifel et al., 1996). NFL 
N-terminus phosphorylation regulates this assembly, with phosphorylation 
promoting isolated NFL disassembly and inhibiting NFL polymerization 
( Hisanaga et al., 1990; Nakamura et al., 1990; Hisanaga et al., 1994). Although it 
is not known whether this process occurs in vivo, reversible NFL assembly is key 
to the integration of NFM and NFH into the NF triplet protein (Nixon and Shea, 
1992). Evidence suggesting that structural alterations of the N-terminus can 
induce significant impairments in NF assembly include the observations that 
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N-terminus deletions of the NFL gene yield assembly-incompetent NFL 
polypeptides (Gill et al., 1990), resulting in a profound accumulation of 
cytoskeletal NF aggregates within motor neurons leading to motor neuron 
degeneration or dysfunction (Lee et al., 1993; Lee et al., 1994; Wong et al., 1995; 
Brown and Hoh, 1997; Rao et al., 1998; Lariviere and Julien, 2004). Through 
these studies, it has become evident that these aggregates have the capacity to alter 
normal cellular functions (Julien et al., 1995; Strong, 2003; Sanelli et al., 2004). 
Obvious decreases in NFL expression have been reported in various types of 
neurodegenerative diseases and normal aging (McLachlan et al., 1988; Clark et al., 
1989; Hill et al., 1993; Kittur et al., 1994; Wong et al., 2000; Menzies et al., 2002). 
Based on this knowledge, the mice deficient in NFL protein was generated by 
using the technique of homologous recombination in embryonic stem cells (Zhu et 
al., 1997). The mice do indeed develop abnormal neurofilament accumulations in 
neuronal perikarya and proximal axons (a common phenomenon in 
neurodegenerative diseases) without obvious signs of motor dysfunction in the 
early stage. This would therefore serve as an ideal model for investigation of the 
temporal relationship between the neuronal aggregates and the activation of glial 
cells (another common phenomenon in neurodegeneration diseases) when 
neurodegeneration is initiated by protein accumulation inside neurons (Li et al., 
2006). Three development stages of neurodegeneration have been clarified in this 
animal model. In the first stage, abnormal neurofilament accumulations form in 
the neuronal perikarya and proximal axons. In the second stage, microglial 
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number increases but the number of aggregate-bearing neurons begins to decline. 
In the last stage, motoneuron numbers decrease with a significant increase in 
numbers of astrocytes (McLean et al., 2005). In the present study, the first stage, 
which is before the significant motoneuron death, has been mainly focused on to 
further explore the relationship between the diseased motoneurons and microglial 
reactions in the lumbar cord segments of NFL−/− mice. 
2. Microglial activation 
2.1 General introduction of microglia 
Del Rio Hortega (1932) was the first to describe microglia in the CNS. By 
silver impregnation techniques, he has characterized a unique cell type in the CNS, 
which has an elongated soma bearing processes extending from both poles of the 
cell, the ramified microglia. The existence of ramified microglia was further 
confirmed by electron microscopy in the 1960s. As a consequence of their 
adaptation to the CNS environment, resting microglia have a unique ramified 
morphology. Nowadays, microglia can unequivocally be distinguished from other 
resident, nonneuronal cells in the CNS by immunocytochemistry. Resting 
microglia constitutively express the complement type-3 receptor (CR3; 
CD11b/CD18 complex) which is further upregulated upon activation. 
The origin of ramified microglia has been a longstanding controversial 
issue (Ling and Wong, 1993; Fedoroff et al., 1997). Bone marrow-derived cells 
(mesodermal elements) or, alternatively, neuroectodermal matrix cells (which also 
serve as precursor cells for astrocytes and oligodendrocytes) have been suggested 
INTRODUCTION                                                    15
as developmental sources of microglia. The observation that the decline of 
blood-derived amoeboid cells in the CNS during the first postnatal weeks was 
accompanied by a dramatic increase in the number of ramified microglia was 
suggestive for a transition of amoeboid cells into resident ramified microglia 
(Ling and Wong, 1993). However, transitional forms between brain macrophages 
and resting microglia could not be detected in the developing brain in mice 
receiving bone marrow transplants from transgenic mice and only 10% of 
parenchymal microglia displayed the transgenic signal (de Groot et al., 1992). In 
adult animals, the attempts to directly demonstrate the replacement of ramified 
parenchymal microglia from bone-marrow-derived precursors so far yielded 
inconclusive results. It turned out that ramified microglia in the adult CNS were 
an extremely sessile cell population exhibiting virtually no turnover from 
circulating monocytic precursor cells (Lassmann et al., 1993). Based on their 
findings that astroglial cultures initiated from newborn mouse neopallium 
contained bipotential progenitor cells, that could give rise to both astrocytes and 
microglia. Fedoroff and colleagues put forward the idea that parenchymal 
microglia are of neuroectodermal origin as all other glia (Richardson et al., 1993; 
Fedoroff et al., 1997;). This is in accordance with findings of De Groot et al. 
(1992) showing that the majority of microglia lacked the transgenic signal after 
bone marrow transplantation. Despite the uncertainty about their origin, microglia 
share most surface molecules  (Flaris et al., 1993) and functional properties with 
bone-marrow derived macrophages.  
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2.2 Characteristics of microglial activation 
Although the details of microglial activation may vary somewhat 
depending on the type of injury, it is possible to generalize that microglial 
activation is marked by a number of characteristic events affecting cellular 
morphology, cell number, migration, phagocytosis and, at a molecular level, the 
pattern of cell surface molecules expressed (immunophenotype) as well as the 
pattern of cytokines and growth factors produced.  
2.2.1 Increase in numbers and migration 
 In a diseased area or injury site of the CNS, the microglial population is 
presented in much higher density as a result of increase in microglial proliferation 
and migration. For example, following axotomy, resting microglia in the CNS 
were reported to proliferate and migrate to tightly ensheath injured motoneurons 
(Kreutzberg, 1966; Blinzinger and Kreutzberg, 1968). 
2.2.2 Morphological transformation 
It is well documented that microglial cells exhibit in two different 
morphogical forms, i.e., amoeboid microglia which exist transiently in the 
developing brain and ramified microglia which also occur in the prenatal brain but 
preponderate and contribute to most, if not all, of the microglia in the adult (Ling, 
1981). Microglia in the early stage of brain development show a macrophage-like 
morphology with at relatively large cell body and short processes and are 
generally called “amoeboid microglia” (Ling, 1979). The idea that microglia 
assume various morphological appearances that can be correlated with distinct 
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functional states arose through studies conducted in the facial nerve system (Streit 
and Kreutzberg, 1988). Depending on whether facial motoneurons could 
regenerate after a reversible injury (facial nerve axotomy) or degenerate after 
irreversible injury (ricin intoxication), microglial cells would respond in a 
characteristic fashion. Following axotomy, resting microglia became activated, 
proliferated and tightly ensheathed injured motoneurons with enlarged 
cytoplasmic processes resulting in the displacement of afferent nerve endings 
from the neuronal cell bodies  (Kreutzberg, 1966; Blinzinger and Kreutzberg, 
1968). During degeneration microglia became rounded brain macrophages that 
phagocytose the dying motoneurons (Streit and Kreutzberg, 1987). This concept 
of two morphological forms of microglia has been modified, in that it now 
includes a so-called hyper-ramified state of microglia which represents an 
intermediate stage between the resting and the reactive forms. Hyper-ramification 
of microglia signifies the beginning of microglial hypertrophy, a consistent 
morphological feature of microglial activation in vivo. Although microglia were 
rarely arrested at the hyper-ramification stage during acute pathological instances, 
certain degenerative changes of a more subtle nature, such as those induced by 
chloramphetamines, could elicit widespread microglial hyper-ramification 
(Wilson and Molliver, 1994). 
When the brain is injured or affected by a stimulus, ramified microglia 
morphologically transform into “activated microglia”, which show retracted 
processes and enlarged cell bodies and become proliferative at the affected site. 
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These transformed microglia are functionally activated and appear to be 
implicated in many pathological states.  
2.2.3 Microglial receptors for activation signals 
Of critical importance in the prompt response of microglia to a variety of 
infectious and inflammatory stimuli is their constitutive and inducible expression 
of a large array of surface receptors that trigger or amplify innate immune 
responses. These include pattern recognition receptors implicated in the 
recognition of pathogen-associated molecules; complement receptors; cytokine 
receptors; and receptors that enhance macrophage effector functions after 
interaction with the adaptive immune system. 
2.2.3.1 Pattern Recognition Receptors 
Recognition and elimination of foreign entities by innate immune cells are 
thought to occur through a set of pattern recognition receptors that interact directly 
with microbial structures leading to stimulation of phagocytosis, induction of 
cytotoxic mechanisms and activation of immune genes (Medzhitov and Janeway, 
Jr., 2000). Among these, CR3 and CD14 have been studied extensively. In the 
normal CNS, resting microglia expresse low to moderate levels of CR3 (Akiyama 
and McGeer, 1990), but no CD14 (Dick et al., 1997; Nadeau and Rivest, 2000). 
Through its lectin site, CR3 can bind various microbial molecules and act as a 
powerful mediator of phagocytosis and activator of intracellular signaling 
pathways, including kinase cascades that are critical in leukocyte activation 
(Ehlers, 2000). CD14 was readily upregulated on microglia upon culturing 
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(Becher and Antel, 1996) and in vivo after LPS and TNF-α treatments (Nadeau 
and Rivest, 2000). 
2.2.3.2 Fc and Complement Receptors 
Opsonic receptors are also associated with microglial activation, which 
mediate or enhance phagocytosis through recognition of serum components 
deposited on microbes or altered host components.  These repctors include FcgRI, 
II, and III binding the constant fragment of immunoglobulins (Peress et al., 1993; 
Ulvestad et al., 1994;); CR1, CR3, and CR4 binding the complement component 
C3bi (Barnum, 1999); and C1qRp binding C1q (Morgan et al., 1997). All the 
receptors are expressed on resting microglia, although at lower levels than on 
meningeal, choroid plexus, and perivascular macrophages. Fc and complement 
receptors may mediate target phagocytosis by microglia in all neuroinflammatory 
conditions associated with specific humoral responses against CNS pathogens or 
self-antigens and appropriate activation of complement, respectively. Because 
signaling through CR3 and Fc receptors may promote production of cytokines and 
reactive oxidants, these receptors may also enhance microglial proinflammatory 
and cytotoxic functions in pathological conditions (Colton et al., 1994; van der 
Laan et al., 1996; Williams et al., 1994). In infectious and autoimmune CNS 
diseases, microglia also showed an upregulation in expressions of receptors for the 
complement anaphylatoxins C3a and C5a, which may be implicated in microglial 
chemotaxis and activation (Nataf et al., 1999). 
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2.2.3.3 Other receptors 
Microglia also express receptors for a number of cytokines that are 
produced intracerebrally during inflammation of the CNS. These include receptors 
for pro- and anti-inflammatory cytokines, whose balance should be determinant in 
inducing and regulating microglia immune functions.  
Expression of chemokine receptors has been demonstrated on microglia in 
vitro and in the course of infectious and autoimmune diseases of the CNS 
(Harrison et al., 1998; McManus et al., 1998; Sorensen et al., 1999; Simpson et al., 
2000). Cultured microglia could migrate in response to fractalkine, MIP-1a, 
MIP-1b, MCP-1 and RANTES, indicating a signaling function for most of the 
above receptors (Peterson et al., 1997; Cross and Woodroofe, 1999; 
Maciejewski-Lenoir et al., 1999)  
Evidence has been provided that microglia could produce large amounts of 
PGE2 in vitro (Minghetti and Levi, 1998). PGE2 effects on microglia occurred 
through binding to the EP2 receptor and elevation of intracellular cAMP levels 
(Patrizio et al., 2000). These findings suggest that PGE2 production by activated 
glial cells may be another factor that contributes to the local regulation of 
inflammatory and immune responses.  
2.2.4 Phagocytic properties of microglia 
Microglia are one of the professional phagocytes in the mononuclear 
phagocyte system. They possess a number of specific receptor molecules that 
facilitate this function, including receptors for immunoglobulin (FcR), CR3, and 
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glycation endproducts (Brown, 1991; Ross and Vetvicka, 1993; Westwood et al., 
1994). Both morphological and functional evidence suggests the phagocytic 
properties of microglia. At the light and electorn microscopic levels, it is possible 
to see cytoplasmic vacuoles and lysosomal bodies in microglia, similar to other 
phagocytic cells. In the rat, ultrastructural lectin labeling studies have 
demonstrated that ramified microglia phagocytose synaptic terminals of 
axotomized neurons (Streit and Kreutzberg, 1987). Phagocytosis has been 
reported in ameboid microglia studied in tissue culture where they have been 
shown to ingest foreign objects (latex beads), immunoglobulin-coated 
erythrocytes, and dead cells (Giulian and Baker, 1986;Hassan et al., 1991; Lee et 
al., 1992; Rieske et al., 1989; Williams et al., 1992). Microglia could also 
phagocytose infectious agents, such as bacteria and fungi (Lee et al., 1992).  
2.2.5 Cytotoxicity of microglia 
It is well-known that overactive microglia can release ROS, NO and 
cytokines (Banati et al., 1993; Dheen et al., 2005; Lee et al., 1992; Mogi et al., 
1994; Qin et al., 2002), which might cause vascular damage in addition to 
neurodegeneration. In a study of 617 cases of PD, the total frequency of 
cerebrovascular lesions was higher than that of controls (Jellinger, 2003). Damage 
to the microvasculature in AD and PD includes fragmentation, atrophy, tortuous 
structure, basement membrane thickening, vacuolization and pericytic 
degeneration (Farkas et al., 2000). In summary, overactivated microglia may have 
a role in neuronal loss and vascular damage in diverse neuropathological 
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conditions. A few possible molecules involved in microglial cytotoxicity are 
briefly discussed. 
2.2.5.1 Release of cytokines  
Cytokines are key regulators of innate and adaptive immune responses. In 
the diseased CNS, tissue infiltrating immune cells, CNS associated macrophages, 
microglia and astrocytes have all been identified as sources of cytokines affecting 
CNS-specific inflammation (Aloisi, 2001). However, both in disease conditions 
and culture systems, microglia, rather than astrocytes, appear to be the main 
sources of critical proinflammatroy (such as IL-1β， IL-6 and TNF-α) and also 
other immuregulatory cytokines (such as IL-10 and TGF-β) while interleukine 4 
has not been reported to be secreted from activated microglia (Aloisi, 2001).  In 
fact, the large number of upregulated microglial factors have been grouped into 
pro-inflammatory (such as IL-1β, IL-6 and TNF-α), anti-inflammatory (TGF-β), 
chemotaxis (MCP-1), growth/proliferation (IL-2), immunosuppressive (IL-10), 
trophic (NT-3), and toxic (iNOS) (Aloisi, 2001; Nadeau and Rivest, 2000; Prinz 
and Hanisch, 1999; Hurley et al., 1999; Seo et al., 2004).  
Although it is discovered that microglia may be double-edged swords in 
the CNS, the present study will mainly focus on the cytotoxic role of microglia. 
Many studies have revealed the toxic and cell death-inducing potential of 
cytokines, such as TNF-α (Aloisi, 2001; Carlson et al., 1999; Mason et al., 2001). 
Cytokines can induce secondary reactions in endogenous or infiltrated cells, 
which are harmful for neuronal cells. Cytokines of microglial origin can assist in 
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the process of leukocyte invasion via enhanced expression of endothelial adhesion 
molecules and chemotactic guidance. Microglia can stimulate lymphocytes by 
presenting antigen in conjunction with costimulatory signals and the release of 
cytokines (Hanisch, 2002). However, excessive recruitment of these microglial 
functions certainly has a profound impact on detrimental neuroinflammation and 
autoimmune defects.  
2.2.5.1.1 IL-1β  
IL-1β is a crucial microglial effector cytokine. As an 
immunostimulatory/proinflammatory signal, IL-1β has a strategic position in 
innate defense and immune responses (Blasi et al., 1990; Dinarello, 1998). IL-1β 
seems to be implicated in many neuropathological scenarios (Allan and Rothwell, 
2001). Activated microglia and invading immune cells could serve as major 
sources of IL-1β upon infection, ischemia, stroke, excitotoxicity, and mechanical 
injury (Hanisch et al., 2001). Following neurotrauma, IL-1β is rapidly released 
(Fassbender et al., 2000). Even though the etiology of CNS disorders varies, IL-1β 
appears to be a common link in processes leading to neuronal death (Rothwell, 
1997; Loddick et al., 1998; Rothwell and Luheshi, 2000). Suppression of 
endogenous IL-1β appears to have neuroprotective effects. 
2.2.5.1.2 TNF-α and Relatives  
Increased levels of TNF-α in the brain have been observed especially after 
injury or ischemia, in bacterial and viral infections, as well as in multiple sclerosis 
and AD. On injury, activated microglia are an early and prominent source of 
INTRODUCTION                                                    24
TNF-α (Gabay et al., 1997). Depending on the stimulus, even a short exposure 
could be very effective and result in strong and lasting release response (Hanisch 
et al., 2001). Thus, in the CNS insults, rapid induction of microglial TNF-α 
production could critically influence subsequent events. Microglia can also release 
soluble TNF receptor II (sTNF-R II), hence affect the bioavailable TNF pool and 
probably regulate potential TNF consequences, but TNF: sTNF-R ratios may vary 
with the type of stimulation. 
Harmful outcomes of increased TNF-α may be related to its activity to 
promote inflammation and edema, although TNF-α administration in animals has 
been reported to cause only minor inflammatory changes until paired with a 
pathogenic stimulus (Angstwurm et al., 1998). High CSF levels of TNF-α may 
indicate poor prognosis after infection. Microglial TNF-α may also be critical in 
boosting a recently identified chemokine-induced and TNF-mediated glutamate 
release from astrocytes (Bezzi et al., 2001). In addition, TNF-α has direct toxic 
effects on neuronal structures and myelin. In contrast, TNF-α has been shown to 
promote neural cell survival and proliferation. Deficiency in TNF-α signaling 
makes animals more susceptible to conditions evoking neuronal damage, probably 
relating to an impaired NGF induction. Apparently, low levels of TNF-α have 
neuroprotective consequences, whereas high levels can cause destructive 
outcomes. TNF-α thus stands for the occasionally opposing actions of several 
cytokines (Carlson et al., 1999; Mason et al., 2001). 
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2.2.5.1.3 Generation of nitric oxide 
Nitric oxide (NO) is a short-lived free radical and intercellular messenger 
that mediates a variety of biological functions, including vascular homeostasis, 
neurotransmission, antimicrobial defence, and antitumor activities (Nathan and 
Xie, 1994). Three isoforms of NOS have been identified and classified into two 
major categories, namely, constitutive and inducible NOS. Neuronal and 
endothelial NOSs, which are constitutively expressed and activated by calcium 
and calmodulin, are called constitutive NOSs (Nathan and Xie, 1994). Of the three 
NO synthases, inducible NO synthase (iNOS), the high-output isoform, is the 
most widely expressed in various cell types after its transcriptional activation (Xie 
and Nathan, 1994).  
In mixed glial cultures stimulated with LPS, microglia have been shown to 
be immunoreactive for iNOS and are the primary source of nitric oxide (NO) 
(Vincent et al., 1996). Expression of iNOS could be induced in cultured rodent or 
human microglia by LPS (Fiebich et al., 1998) or by IFN-γ combined with LPS or 
TFN-α (Corradin et al., 1993; Colasanti et al., 1995; Kim et al., 1998;). 
Additionally, gangliosides (Pyo et al., 1999), recombinant HIV-1 Tat protein 
(Polazzi et al., 1999), bacteria (Girard et al., 2000), and chromogranin A 
(Taupenot et al., 1996) have all been shown to increase iNOS expression in 
microglia. NO released into the media, on the other hand, could inhibit its own 
production (Colasanti et al., 1995) and down-regulate LPS-stimulated prostanoid 
(Minghetti et al., 1996) or TFN-α synthesis (Paris et al., 2000). Prostaglandins 
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like PGE2 (Minghetti et al., 1997; Fiebich et al., 1998; Koppal et al., 2000), basic 
FGF (Colasanti et al., 1995), α-MSH (Galimberti et al., 1999), the glucocorticoids 
dexamethasone and RU 28362 (Tanaka et al., 1997), cannabinoids (Waksman et 
al., 1999), and sodium salicylates (Kim et al., 1998) have been reported to 
suppress iNOS mRNA expression in microglia. 
2.3 LPS induced microglial activation and involved MAPK signaling 
pathways 
From above literature reviews, the important functional role of microglia 
in neuropathogenesis has been clearly demonstrated. In order to understand 
mechanisms of microglial activation and their function, microglial cells in cultures 
have been employed widely as a model. Lippopolysaccoride (LPS) serves as a 
common stimulator to activate microglia. LPS is a bacterial endotoxin known to 
activate microglia, resulting in increases in microglial proliferation, phagocytosis, 
migration and upregulation in expressions of CR3, iNOS, and  inflammatory 
cytokies such as IL-1β, TNF-α and IL-6 (Quan et al., 1994). The later, in turn, 
serve as endogenous inflammatory mediators that contribute to the 
neurodegenerative process (Jeohn et al., 2000; Gayle et al., 2002; Wenk et al., 
2004).  
CD14 and β2 intergrins (CD11b/CD18) function as LPS receptors (Wright 
and Jong, 1986; Wright et al., 1990; Wright et al., 1991; Medvedev et al., 1998), 
however, CD14 is not capable of initiating a transmembrane activation of the 
signal, because it is a glycosylphosphatidylinositol-anchored protein. LPS must 
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interact with a transmembrane receptor(s) such as TLRs and integrins that are 
responsible for signal transduction. Recently, these membrane-associated 
molecules CD14, CD11b/CD18 (completement receptor 3 or CR3) and TLR4 
have been postulated to form an activation complex (cluster) for LPS-signaling 
(Perera et al., 2001). These studies support the importance of CR3 in LPS 
stimulated signaling pathways in microglia. Although LPS does interact with CR3 
(CD11b/CD18), subsequent studies performed on monocytes and macrophages 
derived from CD18-deficient patients found normal levels of TNF-α and IL-1β 
and led to the conclusion that CD18 is not essential for cellular responses to LPS 
(Wright et al., 1990), suggesting that CD11b (the α subunit of CR3) may play an 
important role in regulating LPS induced microglial activities and involved 
signaling pathways.  
Most cellular responses to extracellular stimuli are mediated by kinase and 
phosphatase cascades. One of the most important kinase families in inflammatory 
cells is mitogen-activated protein kinases (MAPKs). They are strongly conserved 
through evolution, suggesting their vital role in intracellular signaling (Marshall, 
1994; Cobb and Goldsmith, 1995; Marshall, 1995; Sugden and Clerk, 1997). The 
MAPK family comprises four subfamilies in mammalian cells. These include (1) 
extracellular signal-regulated kinases (ERK1/2; also known as p44/42 MAPK); (2) 
c-jun N-terminal kinases (JNKs), also called stress-activated protein kinases 
(SAPKs); (3) ERK5/big MAP kinase 1 (BMK1); and (4) p38 MAPKs. 
Traditionally, the ERK1/2 or p44/42 MAPK pathway has been connected with the 
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regulation of cell growth and differentiation (Cobb et al., 1991; Sugden and Clerk, 
1997; Ono and Han, 2000;) but, at least in the brain, ERK1/2 or p44/42 MAPK is 
also involved in cellular responses to stress stimuli, including oxidative stress, 
glutamate receptor stimulation, or increases in intracellular calcium levels ( Fiore 
et al., 1993; Rosen et al., 1994; Aikawa et al., 1997). The JNK group of MAPKs 
can be activated by various stressful stimuli, such as oxidative stress, deprivation 
of trophic factors, and activation of death domain receptors by extracellular 
TNF-α or FasL (Ip and Davis, 1998; Mielke and Herdegen, 2000). The BMK1 
MAPK signaling pathway has been shown to regulate serum-induced early gene 
expression through the transcription factor MEF2C (Kato et al., 1997). The p38 
MAPK family is associated with signaling pathways that are activated by 
inflammatory stimuli, but is also involved in cell cycle, cell growth, and 
differentiation (Kyriakis et al., 1994; Herlaar and Brown, 1999; Mielke and 
Herdegen, 2000; Ono and Han, 2000). P38 and p44/42 MAPKs are serine 
threonine kinases that are localized in the cytoplasm until activated by dual 
phosphorylation on both Tyr and Thr residues (Chen et al., 1992; Sanghera et al., 
1992; Seth et al., 1992; Gonzalez et al., 1993; Raingeaud et al., 1995). P38 
MAPKs have the Thr-Gly-Tyr dual phosphorylation motif, and p44/42 MAPKs 
are phosphorylated at the Thr-Glu-Tyr motif (Hanks and Hunter, 1995).  
Both microglial activation and activation of p38 MAPK or p44/42 MAPK 
pathways occur in most chronic neurodegenerative diseases and acute brain 
injuries and their animal models (Koistinaho and Koistinaho, 2002). Even though 
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there are no in vivo experiments indicating that bacterial infections could induce 
p38 or p44/42 MAPK pathways in microglia, several in vitro studies have 
demonstrated that LPS, a cell wall component of gram-negative bacteria thought 
to be responsible for pathophysiological sequelae of bacterial infections, is a 
strong stimulant for both p38 and p44/42 MAPK pathways. The LPS-induced NO 
and TNF-α release appear to require both p38 and p44/42 MAPK activities (Bhat 
et al., 1998; Pyo et al., 1998; Lee and Yea, 2000).  
3. Complement receptor 3 
As mentioned above, the CR3 is an important receptor for LPS-induced 
microglial activation. The CR3 is a heterodimeric surface receptor consisting of a 
95-kDa β subunit (CD18) and 165-kDa α subunit (CD11b) and belongs to the 
leukocyte β2 integrin superfamily that shares the same CD18 beta chain as LFA-1 
(CD11a/CD18) and CR4 (CD11c/CD18). They are expressed on the surface of 
neutrophils, monocytes, macrophages, and NK cells and are involved in numerous 
cell-cell and cell-substrate interactions (Perera et al., 1997; Hynes, 2002;). 
Recently the availability of CD11b knockout mice has provided researchers with a 
means to more clearly investigate the numerous functions of CR3 (Coxon et al., 
1996; Lu et al., 1997; Tang et al., 1997; Dong et al., 1997; osenkranz et al., 1998; 
R Bhat et al., 1999; Soriano et al., 1999; Xia et al., 1999; Melo et al., 2000). 
However, to date, the work published from experiments using CR3 knockout 
animals has been largely restricted to the role of CR3 in mediating cellular 
adhesion events. Despite uncertainties regarding the molecular details, CR3 
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clearly interacts with LPS and other diverse microbial glycoconjugates. This 
activity adds considerably to a role for CR3 in innate immunity (Perera et al., 
1997; Ehlers, 2000).  
3.1 Structure of CR3 and ligands 
Structural characteristics of CR3 allow it to recognize very different 
ligands, including complement fragment iC3b, intracellular adhesion molecule-1 
(ICAM-1), and bacterial products (Diamond et al., 1991; Bilsland et al., 1994; 
Hetland and Wiker, 1994; Thornton et al., 1996). This promiscuity makes CR3 an 
important receptor for phagocytosis and clearance of several bacteria 
(Agramonte-Hevia et al., 2002). Most ligands for CR3 are recognized by its α 
chain, which is a type 1 transmembrane protein composed by three domains: 
extracellular (1092 residues), transmembrane (26 residues) and cytoplasmic (19 
residues). The amino-terminal half of the extracellular domain consists of seven 
repeats with weak homology to one another denoted Phe-Gly-Gly-Ala-Pro 
(PGGAP) repeats. These seven amino-terminal FGGAP repeats fold into a 
b-propeller conformation (Oxvig and Springer, 1998) that contains seven b-sheets 
(called W1 to W7). Each b-sheet consists of four antiparallel b-strands, ordered 
around a pseudosymmetry axis like blades in a propeller (Oxvig et al., 1998). 
These repeats are interrupted by the insertion of a domain of approximately 200 
amino acid residues called the I domain (Balsam et al., 1998; Hynes, 2002). The I 
domain binds to the complement molecule iC3b (Bilsland et al., 1994), and also to 
the M. tuberculosis antigen 85C expressed on the bacterial surface (Hetland and 
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Wiker, 1994). The carboxyl-terminal end of the extracellular portion of the CR3 
α-chain contains a lectin like C-domain involved in binding to M. tuberculosis 
oligosaccharides (Thornton et al., 1996).  
3.2 CR3 is a remarkably versatile adhesion and recognition receptor and a 
primary phagocytic receptor  
CR3 is able to mediate C3-independent binding and uptake of various of 
microbes and microbial cell wall componets, such as Escherichia coli (Wright and 
Jong, 1986a), lipopolysaccharide (Wright et al., 1989), Staphylococcus 
epidermidis (Ross et al., 1985c), Leishmania species (Mosser and Edelson, 1985), 
Leishmania glycoprotein gp63 (Russell et al., 1989) and lipophosphoglycan 
(Talamas-Rohana et al., 1990), Histoplasma capsulatum (Bullock and Wright, 
1987), beta-glucan (Ross et al., 1987), and Bordetella pertussis hemagglutinin 
(Relman et al., 1990). Binding of those ligands to the receptor was inhibited by 
antibodies to the alpha chain of CR3 directed at the C3bi site (Wright et al., 1989; 
Russell et al., 1989), to lectin-like sites (Ross et al., 1987; Ross et al., 1985a), or to 
the leukocyte adhesion molecule common beta chain (Ross et al., 1985b). Thus, 
CR3 is implicated to possess multiple sites through which inflammatory microbes 
may bind, either directly or via fixed C3, and activate phagocyte functions (Ross 
et al., 1985a; Ding et al., 1987).     
From the findings described above, it is clear that CR3 can induce 
phagocytosis by different mechanisms. It can participate in phagocytosis of 
complement-opsonized bacteria (Frank and Fries, 1991) and also in nonopsonic 
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phagocytosis through recognition of bacterial oligosaccharide residues on the 
bacteria surface (Wright et al., 1990; Le, V et al., 2002). CR3-mediated 
phagocytosis of particles coated with iC3b is a type II phagocytosis, characterized 
by the sinking of particles into the cell and activation of the small GTPase RhoA 
(Wright et al., 1990; Le, V et al., 2002). Whereas, nonopsonic CR3-mediated 
phagocytosis is a type I phagocytosis, characterized by pseudopodia extensions 
and activation of different enzymes including Hck, Rac, and Cdc42 (Le, V et al., 
2002).  
Binding of iC3b to CR3 triggers signals that activate cytoskeletal 
reorganization, gene transcription and the release of cytokines. These cell 
responses, in turn, promote phagocytosis and effective killing of bacteria. The 
exact signal transduction pathways initiated by CR3 aggregation on the cell 
membrane are not completely known. CR3 signaling involves activation of Src 
family tyrosine kinases, such as Fgr, Hck, and Lyn, phosphorylation of 
cytoskeletal proteins, and changes in cytosolic calcium concentration (Dib, 2000). 
After iC3b binding, the β subunit of CR3 (CD18) mediates activation of tyrosine 
kinases and the recruitment of the cytoskeletal proteins actinin, paxillin and talin 
(Berton et al., 1994). Activation of tyrosine kinases by CR3 leads to the 
phosphorylation of the isoform 2 of phospholipase C-g (PLCg), which promotes 
the release of calcium from intracellular stores (Hellberg et al., 1996), and a 
subsequent calcium influx from the extracellular medium (Pettit and Hallett, 
1996). The marked increase in cytosolic calcium concentration activates 
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actin-severing proteins (Hendey et al., 1992) which would participate in the 
reorganization of the actin cytoskeleton. 
An alternative CR3-mediated phagocytosis is to cooperate with a second 
phagocytic receptor. It has been shown in both neutrophils and transfected cells 
that CR3 cooperated with FcçRIII to stimulate a respiratory burst and to facilitate 
antibody dependent phagocytosis (Krauss et al., 1994; Zhou and Brown, 1994). 
These results, have emphasized on the importance of receptor cooperativity 
involving CR3, which parallels the general tendency for integrins to cluster and to 
form signaling complexes with other cell surface receptors and with cytoplasmic 
proteins (Giancotti and Ruoslahti, 1999). 
CR3-mediated phagocytosis classically results in a tight-fitting, zippered 
phagosome, whereas FcR-mediated phagocytosis produces a more spacious 
phagosome. Caron and Hall (Caron and Hall, 1998) have shown that 
CR3-mediated phagocytosis is dependent on the activity of Rho, whereas 
FcR-mediated phagocytosis depends on Cdc42 and Rac. These differences may 
account for observed differences in cellular events following CR3- versus 
FcR-mediated phagocytosis, such as absent respiratory burst and failure to elicit 
proinflammatory signals during CR3-dependent phagocytosis. 
3.3 Other studies on CR3 
3.3.1 CR3 and reactive oxygen and nitrogen intermediates. 
Nitric oxide (NO) synthase is inducible in murine macrophages by 
cytokines and/or LPS (Nussler and Billiar, 1993). Inducible NO synthase in 
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macrophages could generate large amounts of NO during inflammatory reactions 
and during infection (Nussler and Billiar, 1993). NO plays an important 
antimicrobial role in various bacterial (Beckerman et al., 1993; Summersgill et al., 
1992), fungal (Granger et al., 1988), and parasitic (Nussler and Billiar, 1993) 
infections, probably via inhibition of iron-containing enzymes and/or formation of 
additional toxic radicals by phagocytes following its combination with O2- radicals 
(Nussler and Billiar, 1993). Macrophage can kill invading organisms via reactive 
oxygen intermediates (ROI) (Jackett et al., 1983) and reactive nitrogen 
intermediates (RNI) (Flesch and Kaufmann, 1991). 
CR3 has been shown to play a dominant role in the stimulation of a 
neutrophil superoxide burst mediated by zymosan and b-glucan particles (Ross et 
al., 1987a) and CD11b-/- mice have been shown to be deficient in oxygen radical 
formation (Coxon et al., 1996). In addition, CR3 molecule acts in a 
CD14-independent signaling pathway and contributes to NO production generated 
by the macrophage in response to high doses of LPS (Haziot et al., 1996; Perera et 
al., 1997). 
3.3.2 CR3 and cytokines 
It has been implicated that CR3 may play a critical role in mediating 
cytokine induction in cultured cells stimulated by heat-killed Group B 
Streptococcus (GBS) in vitro (Cuzzola et al., 2000; Cuzzola et al., 2000; 
Medvedev et al., 1998). GBS-induced TNF-α release was inhibited by monoclonal 
antibodies directed against the receptor. Blood derived from CR3 
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(CD11b/CD18)-deficient mice demonstrated a markedly diminished TNF-α in 
response to GBS. In addition, macrophage cell lines expressing CR3, but not the 
WEHI 3 line lacking of CR3, produced detectable TNF-α after GBS stimulation 
(Goodrum et al., 1995). 
Anti-CR3 monoclonal antibody blocking may prevent not only 
streptococci-induced TNF-α production, but also TNF-α toxicity. This was 
suggested by the report that tissue injury and cardiopulmonary changes induced 
by recombinant TNF-α infusion was prevented by anti-CR3 antibody (Eichacker 
et al., 1992). However, anti-CR3 approaches should be considered with great 
caution in view of the important role of these molecules in host defenses. Patients 
with congenital defects in the CD18/CD11b complex have impaired neutrophil 
functions (Wright et al., 1989; Wright et al., 1990). In addition, anti-CD18/CD11b 
antibodies exacerbated infection in animals challenged with E. coli (Eichacker et 
al., 1992), S. aureus (Sharar et al., 1991) or L. monocytogenes (Rosen et al., 1989). 
These detrimental effects likely occurred, at least in part, due to decreased 
neutrophil adhesion to vascular endothelium and recruitment in infected sites. 
Although it has been reported that binding of streptococci to CR3 could be 
selectively blocked without affecting the ability of this receptor to mediate cell to 
cell interactions involved in host responses (Cuzzola et al., 2000), these findings 
can not exclude that, in addition to CR3, other membrane receptors in microglia 
may also be involved in such activities. 
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3.3.3 CD14-independent actions of CR3 in LPS stimulation signaling 
pathways 
In addition to CD14, CR3 and CR4 have been reported in mediating cell 
activation in response to LPS treatment. Translocation of NF-kB in Chinese 
hamster ovary cells transfected with CR3 or CR4 cDNA confirms the ability of 
CR3 to respond to LPS (Ingalls and Golenbock, 1995; Ingalls et al., 1997). CR3 
and CD14 have a cross-talk correlation in mediating LPS signaling, as evidented 
by the report that stimulation of neutrophils with LPS in the presence of serum or 
the LPS binding protein leads to association between CR3 and CD14, with 
subsequent dissociation of CD14-CR3 complexes as cells attach to substrates 
(Zarewych et al., 1996). However, peripheral blood mononuclear cells obtained 
from CD18-deficient patients could bind and respond to LPS normally (Wright et 
al., 1990), suggesting that CD14 could mediate LPS effects independent of CD18 
expression.  
A number of observations have shown that high doses of LPS can activate 
cellular responses by a CD14-independent mechanism (Kitchens et al., 1992; 
Delude et al., 1995; Haziot et al., 1996; Perera et al., 1997). These results suggest 
the existence of receptor molecules distinct from CD14 that are responsible for the 
signaling effects of LPS. In this respect, expression of CR3 or CR4 in CHO cells 
has been reported to enable NF-kB translocation in response to LPS (Ingalls and 
Golenbock, 1995; Ingalls et al., 1997). In addition, CR3 binds unopsonized 
bacteria and LPS to macrophages, monocytes, and granulocytes (Wright and Jong, 
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1986), and associates with CD14 on the surface of human neutrophils after 
stimulation with LPS (Zarewych et al., 1996). Thus, it is plausible that the integrin 
receptors represent phagocyte receptors which are capable of mediating LPS 
effects in the absence of CD14. 
4. Hypothesis  
Adult onset neurodegenerative diseases are the main causes for disability, 
dementia, and death in elderly people. So far, there is no effective cure for these 
diseases owing to the lack of understanding of neuropathogenesis of the diseases. 
As the clinically characterized autopsy tissues may represent only a late stage of 
the disease processes, the knowledge on early pathogenesis, which is more 
important for diagnosis and treatment of the diseases, is still significantly 
insufficient. An understanding of early pathological changes, such as motoneuron 
loss and microglial activation, before any clinical symptom is therefore of 
paramount importance. 
 Activated microglia are found in the end stage of all neurodegenerative 
diseases. Although the cause or effect relationship between microglial activation 
and neuronal degeneration is still not fully understood, it is evident that the 
inflammatory events mediated by microglial activation contribute to several 
neurodegenerative processes (Wyss-Coray and Mucke, 2002; Wyss-Coray, 2006). 
No matter whether the inflammatory reaction from activated microglia or 
mal-alteration in neurons is the initiative causative factor for a neurodegenerative 
disease, it has been assumed in the present study that neuropathogenesis should 
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be detectable before occurance of neurological signs in a neurodegenerative 
disease. There might be a “golden time” for treatment at early stage of the disease 
when the diseased neurons might be still curable and pathological changes 
reversible. The key issue in the present study was therefore to detect 
neuropathological changes in the early stage of neuropathogenesis. 
There are three possibilies for the microglia-neuron interaction in the early 
stage of neuropathogenesis of neurodegenerative diseases: a) Microglial reaction 
may occur before neurodegeneration, i.e., microglial reaction could result in 
neurodegeneration; b) Microglial reaction may occur after neurodegeneration, i.e., 
microglial reaction may be induced by pathological changes in neurons; and c) No 
microglial reaction before the onset of clinical neurological signs of 
neuropathogenesis even if neuronal degeneration has occurred, i.e., there may be 
no relationship between microglial reaction and neuronal degeneration. In the 
present study, the mice with defects in neurons have been employed to investigate 
if the neurodeneration being an initiative pathological change could lead to a 
microglial reaction. It is assumed that the degenerating neurons at the ealy 
stage could release signals to surrounding non-neuronal cells, especially 
microglia.  
During the past decade, mechanisms involved in the immune surveillance 
of the CNS have come to the fore in neuropathological research mainly because of 
the recognition that most neurological injuries and disorders involve activation 
and, possibly, dysregulation of microglia. Activated microglia displays an 
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up-regulation of a variety of surface receptors, including the complement receptor 
type 3 (CR3). The CR3, a member of β integrin family consisting of a 95-kDa β 
subunit (CD18) and a 165-kDa α subunit (CD11b), serves as one of the earliest 
markers to be upregulated on activated microglia (Gehrmann et al., 1995) and its 
increase has been reported in virtually all pathological conditions. However, it is 
less clear about the involvement of the CR3 at the early stage of 
neurodegenerative diseases: How would this receptor respond toward the 
development of neurodegeneration and what function of microglia would be 
determined by stimulating of this receptor? Nevertheless, detectable alteration, 
either upregulation or downregulation, in expression of the CR3 has been 
assumed in the present study. 
5. Scopes of research 
Although adult onset neurodegenerative diseases are still challenging 
problems in healthcare as there are no therapeutic solutions for most of these 
neurodegenerative diseases, in vivo experiments provided compelling evidence for 
the possibility of conquering the diseases. It has been showed that if pathological 
changes in motoneurons developed during the inhibition of microglial activation, 
the pathogenesis could be reversed (Strong et al., 1995; He and Strong, 2000;). 
The contradictory facts that many in vitro experiments have shown the possibility 
to save degenerated neurons from death and the failure of many clinical trials 
(Thatte and Dahanukar, 1997) raise a crucial issue in the therapeutic strategy: 
When is the proper time to deliver the treatment? It may be too late to treat those 
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clinically diagnosed neurodegenerative diseases because impairment imposed on 
neurons may become irreversible at the time when symptoms occur in the patient. 
Therefore, the present study has mainly aimed:  
 
5.1 To study the development of neurodegeneration at the early age of the NFL-/- 
mice. The results would provide information on possibility to use this transgenic 
mouse as an animal model to study glial reaction in the early stage of 
neurodegeneration. 
 
5.2 To study glial reactions, especially microglial activation, in the early stage of 
development of neurodegeneration during which abnormal protein aggregates has 
formed in motoneurons but no neuron death have appeared in the NFL-/- mice. 
The present study may shed more lights on the understanding of 
neuropathogenesis at earlier stage of neurodegenerative diseases and provide 
fundamental bases for earlier diagnosis and drug development for the diseases. 
 
5.3 To investigate the possible function of microglial reaction toward degenerating 
neurons in early stage of neurodegeneration, especially the involvement of the 
CR3 in such a response. The results obtained might support the notion that 
modulating microglial function might decrease the cytotoxicity in the 
microenvironment of diseased neurons and therefore delay or stop the progress of 
neuronal degeneration. 
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1. Animal 
The NFL−/− mice were gifts from Dr. J.P. Julien. The C57BL/6 mice, on 
which the NFL (−/−) mice were developed, were obtained from the Laboratory 
Animal Centre of the National University of Singapore. The housing of and 
surgical procedures on the mice were in accordance with the guidelines of the 
International Guiding Principles of Animal Research throughout the period of the 
study. All efforts were made to minimize the number of animals used and their 
suffering. Under the same condition, age-matched C57BL/6 mice served as the 
controls for the NFL−/− mice in all animal experiments. 
The DNAs extracted from the mouse tail were screened by polymerase 
chain reaction (PCR) using primers (forward: 5′-ACA GCC TGA TGG ACG AGA 
TAG-3′; reverse: 5′-GCT TCT CAG CTC ATT CTC CAG-3′) to monitor NFL 
gene in the NFL−/− mice (McLean et al., 2005). 
A total of 75 male NFL-/- mice aged at 1, 3 and 6 months were used in the 
present study: 30 mice were used for immunostaining of NFH, NFM, CD11b, 
Iba-1, GFAP, fifteen were used for Electron Microscopy, 15 for sciatic nerve cut 
and 15 for mRNA work. Seventy-five age- matched C57BL/6 mice served as the 
controls. 
2. Anesthesia 
Prior to surgery, perfusion or harvesting of tissue samples or cells, all 
animals were deeply anaesthetized by an intraperitonal injection of 7% chloral 
hydrate (5 ml/kg body weight). After 10-15 minutes, a foot pad of the animal was 
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pinched with a pair of toothed forceps to ensure the animal was under full 
anesthesia. All procedures involving animals were approved by Institutional 
Animal Care & Use Committee, DSO National Laboratories, Singapore. 
3.  Sciatic nerve cut model 
In order to elucidate if there would be any alteration in the ability of glial 
reaction toward a harmful stimulation after the targeted disruption of NFL in the 
mouse, the right sciatic nerve was sectioned at the mid-thigh level under 
anaesthesia, a well established experimental model in this lab. The operated mice 
were allowed to survive for 1, 3, and 5 days, with 5 animals for each type of mice 
at each time point.  
4.  Histopathological observations  
10 NFL-/- and 10 C57BL/6 mice were sacrificed for Nissle staining and 
immunocytochemistry of NFH, NFM, CD11b, Iba-1 and GFAP at each time point 
(1, 3 and 6 months of age). 
4.1. Perfusion  
4.1.1 Fixatives  
2% PLP (1000 ml) 
L-Lysine                                                13.7g  
D.H2O                                                 375 ml 
 
0.1M Solution ‘B’                                                             
(178g Na2HPO4.2 H2O in 10 litres Deionised H2O     125 ml 
     
0.1 M Solution ‘A’  
(69g NaH2PO4. H2O in 5 litres Deionised H2O)               ±250 ml 
Phos. Buffer     
                                                                            
(Add approx 1 volume of ‘A’ to 3 volume of ‘B’ till PH 7.4) 
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8% PF                                      20g PF/250 ml H2O 
1N NaOH                                         2.5-7.5 drops                
 
Sodium m-periodate                                       2.14g                
4.1.2 2% PLP preparation 
All fixatives used in the present study were freshly prepared before use. 
Step 1: 8% PF were prepared by heating paraformaldehyde powder in 
distilled water and add appropriate drops of 1N NaOH until PF powder is fully 
dissolved. Then the conical flask containing 8% PF was put in iced water. 
Step 2: Prepare L-Lysine solution by resolving L-Lysine in distilled water. 
PH value of the solution was adjusted to 7.4 by solution ‘B’. 
Step 3: Mix 8% PF (cold) and L-Lysine solution together and then add 
appropriate amount of sodium m-periodate into the mixture. 
4.1.3 Perfusion procedure 
Two reservoirs were used, one containing Ringer’s solution and the other 
appropriate fixative. Each reservoir was connected to a long polythene tube with 
an air trap interposed between them. A 19G winged needle (Terum Co., Japan), 
serving as cannula, was connected to the tube. Before introducing the perfusion 
fluid to the heart, all air bubbles in the tubes connected the two reservoirs were 
removed. Perfusion was done under gravity with the two reservoirs fixed at a 
height of 100cm above the perfusion table. 
A midline incision of the skin from the level of the suprasternal notch to 
the level above the symphysis pubis was made. The incision, made through the 
skin and muscles of the anterior abdominal wall, was extended bilaterally along 
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the subcostal margins to expose the sternum and diaphragm. The latter was then 
cut along the subcostal margin to fully expose the heart. Care was taken during 
this process not to damage the lungs. The pericardium was then slit with a pair of 
fine scissors to fully expose the heart. Perfusion was initiated whereby a cannula 
with some Ringer’s solution dripping slowly from its tip was inserted into the left 
ventricle and was immediately followed by slitting a portion of the right atrium to 
let out the blood, and subsequently the perfusate. Once the cannula was secured in 
place, the flow of the Ringer’s solution was turned to full pressure by means of a 
three-way tap. A total of 50 ml of Ringer’s solution at room temperature was 
allowed to flush the vascular system until the lungs and liver were cleared of 
blood. A total of about 200 ml of the fixative (2% PLP) at 4°C was administered. 
4.2 Tissue preparations 
4.2.1 Preparation of gelatinized and salinized slides 
Materials 
5% gelatin solution: 
Gelatin                                                 1.5mg    
Chrome Alum                                            0.15g                
Distilled water                                           100ml                
 
2% saline solution: 
 
Saline                                                    2ml                
Absolute alcohol                                          98ml                
Procedure 
Slides were first dipped in the acid solution (400ml of 98% sulfuric acid 
mixed with 1 tea spoon of potassium dichromate) for 2min, and then washed by 
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running tap water for 10min. The slides were rinsed with distilled water and then 
baked in an oven at 80ºC overnight for drying.  
Gelatinized slides: The following day, dried slides were dipped in the 
gelatin solution and then were hung to dry with the clips. Gelatinized slides were 
kept in an oven at 37ºC for histological or immunohistochemical studies.  
Salinized slides: The dried slides were dipped into absolute alcohol for 2 
min, then in 2% saline solution for 5-10min, and rinsed in absolute alcohol 
followed by deionised water. The slides were dried in an oven at 60ºC and kept at 
37ºC for histological or immunohistochemical studies. 
4.2.2 Preparation of frozen sections 
After perfusion, the brains and lumbar cord segments were dissected, 
along with these, the livers and spleens from unoperated mice were also removed 
for examination of peripheral macrophages. All the tissues were then postfixed 
with 2% PLP for additional 4 hours. The tissues were subsequently transferred to 
0.1M phosphate buffer (pH7.4) containing 15-30% sucrose and kept overnight at 
4°C. The tissue samples were mounted on a metal chuck using Lipshaw M-1 
embedding matrix (Pittsburgh, USA) and rapidly frozen by quenching in liquid 
nitrogen. Transverse sections of 30μm thickness of brainstems were cut using a 
cryostat (Leica CM 3050). The sections were subsequently mounted on 
gelatinized or salinized slides and allowed to dry at room temperature for 1 hour. 
4.3 Transmission electron microscopy  
The lumbar cord segments from the NFL-/- and C57BL/6 mice were fixed 
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in 3% glutaradehyde and 2% formaldehyde in 0.1M phosphate buffer (pH 7.2), 
with 5 animals for each type of mice at each time point (1, 3 and 6 months of age). 
These samples were postfixed in 1 % osmium tetroxide and dehydrated in an 
ascending series of ethanol and embedded in araldite. Ultrathin sections were cut 
and doubly stained in uranyl acetate (10 minutes) and lead citrate (8 minutes) 
before viewing using a Philips CM 120 BioTwin electron microscope. 5 animals 
were used for each type of mice at each time point. 
4.4 Histochemistry and immunohistochemistry studies 
4.4.1 Nissl (Cresyl Fast Violet-CFV) staining 
Materials 
0.25 % CFV stock solution: 
Cresyl Fast Violet (GURR’S, UK)                            0.25g                
Deionised water                                          100ml                
 
CFV staining solution: 
One part of 0.25 % CFV stock solution 
Two parts of 0.2 N acetic acid 
Procedure 
Frozen lumbar cord segments were immersed in CFV staining solution at 
60°C for 5 minutes, followed by differentiation in 70 % ethanol. The sections 
were dehydrated in an ascending series of ethanol and passed through xylene 
before being coverslipped with Permount as mountant. They were then viewed 
under a Nikon light microscope. After Nissl staining, the average numbers of large 
nucleated neurons in the ventral horns from all the sections collected were 
compared and analyzed quantitatively between different animals using Student’s 
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t-test. 
4.4.2 NFH and NFM histochemistry 
The alterations in distribution of NFH (neurofilament heavy subunit) and 
NFM (neurofilament medium subunit) were assessed by immunohistochemistry 
using anti-NFH and anti-NFM (both from Chemicon, USA). Frozen sections of 
the lumbar cord segments were cut at 30 μm thickness using a Jung Frigocut 
2800E at -20°C. One in every five sections was picked up and kept in wells with 
phosphate-buffered saline (PBS) containing 0.1% Triton X-100 (TX) for 
free-floating staining. After washing with PBS-TX 3 times of 10 minutes, sections 
for NFM and NFH staining were incubated with trypsin (0.25%) at 37 °C for 5 
minutes. All the sections (including the trypsin-treated and untreated sections) 
were washed with PBS for 3 times of 10 minutes. The sections were incubated 
with normal bovine serum (1:200) for 20 minutes, followed by incubation in a 
humidified chamber overnight at room temperature with anti-NFH (1:5000), 
anti-NFM (1:2000). After incubation, the antibodies were detected using 
VECTASTAIN ABC kits (Vector Laboratories, USA) with 0.05% 
diaminobenzidine tetrachloride (DAB) (Sigma Chemical Co., USA) as a 
peroxidase substrate. All the sections were picked up from the wells and mounted 
on slides coated with silane. After being dried for 1 hour at room temperature, the 
slides were counterstained with methyl green, dehydrated and then coverslipped 
using Permount.  
For solution preparations used for immunohistochemistry are shown as the 
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below. 
Ⅰ.  0.1 M PBS 
-Disodium hydrogen phosphate heptahydrate                   13.3g                
-Sodium chloride                                          8.5g               
-Distilled water                                          900 ml               
The solution was adjusted to PH 7.4 with 2N HCL and topped up to 1,000 
ml with distilled water. 
 
Ⅱ. PBS containing 0.1% Triton-X 100 (PBS-TX) 
-PBS                                                 1000 ml                
-Triton-X 100                                             1 ml                
 
Ⅲ. 0.05M Tris buffered saline (TBS) 
- Tris base (trihydroxymethylaminomethane)                      6g               
-Sodium chloride                                            8g                
-Distilled water                                     900ml               
            The solution was adjusted to pH 7.6 with 2N HCl and topped up to 
1,000 ml with distilled water. 
 
      Ⅳ. 0.05% DAB solution 
      -DAB                      50 mg               
      -0.05 M TBS                    100 ml               
      -30% Hydrogen peroxide                                   33 μl               
4.4.3 CD11b and Iba-1 histochemistry 
To examine activation of microglia and macrophages in protein aggregates 
bearing NFL-/- mice, anti-CD11b (1:1000, BD Pharmingen, USA) was used to 
immunostain the frozen sections of lumbar cord segments, livers and spleens of 
the unoperated and operated NFL-/- and C57BL/6 mice.  
After staining, microglia with clear cell bodies in all the CD11b stained 
sections from NFL-/- and C57BL/6 mice were counted. All the CD 11b stained 
slides from both operated and unoperated mice were analyzed using Image-Pro 
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Plus software to measure the positive CD 11b staining. In consideration of 
variation in intensities from different immunostained sections, only the numbers 
of positive pixels have been compared between various groups. For each animal, 
at least 5 digital images have been taken at the same magnification under a 
microscope. After the image processed to clone the brown color, the number of 
pixels with positive CD 11b staining (brown in color) was recorded. The data were 
presented as the percentage of positive pixels over the total pixels of the image 
(Manka et al., 2001).  
To verify if the CD 11b and Iba-1 antibodies would label the same 
microglia in the CNS, the free-floating sections from both species of mice at age 
of 3 months, when the number of Iba1-positive microglia increased to maximum 
in NFL-/- mice (McLean et al., 2005), were incubated with rat anti-mouse CD 11b 
(1:1000) and rabbit anti-mouse Iba-1 (1:1000) antibodies overnight. The 
immunoreactions were observed using a Olympus 1X51 microscope after 
application of anti-rat IgG conjugated with Cy3 (red in color) and anti-rabbit IgG 
conjugated with FITC (green in color) for 1 hour. 
4.4.4 GFAP histochemictry 
To examine activation of astrocytes and their response to sciatic nerve cut 
in NFL-/- mice, anti-GFAP (1:3000, DAKO, Denmark) was used to immunostain 
the frozen sections of lumbar cord segments, livers and spleens of the unoperated 
and operated NFL-/- and C57BL/6 mice. 
4.4.5 Measurement of the spinal cord 
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The transverse sections of the lumbar cords from the same level of the 
spinal cords were used to compare difference in the size of the spinal cord 
between two types of mice. A few parameters (refer to Fig. 6), such as horizontal 
diameter across the central canal of sections, were measured using Image-Pro 
Plus. 
4.4.6 Silver staining of neurodegenerative neurons 
Neurodegenerative neurons in the lumbar cord segments of NFL-/- and 
C57BL/6 were stainined by using FD NeuroSilver™ Kit I (FD 
NeuroTechnologies, USA). The procedure is briefly described as the below: 
The frozen sections from the mice were rinsed with distilled water before 
incubated with the solutions provided in the kit, strictly following the protocol in 
the manul book. Thereafter, the sections were mounted on silane coated silde and 
let air-dry. Dehydrate the sections by using absolute alcohol and xylene before 
coverslipped in permount. Finally the sections were examined by using a light 
microscope. Neurons undergoing degeneration were detected by dense silver 
precipitates, appearing as black grains in the cell body. 
5. Detection of selected cytokine expressions in the spinal cord 
The expressions of selected cytokines were detected by using Real-time 
PCR. The total mRNA from the spinal cord of NFL-/- and C57BL/6 mice were 
isolated by using Trizol reagent. 5 animals were used for each type of mice at each 
time point. Detailed methods will be described later in the PCR section.  
6. Functional assessment using rotarod test 
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The rotarod was purchased from Columbus Instruments (USA). The dowel 
is 3 inches in diameter and there is a separate chamber for each mouse. The 
rotarod starts at a speed of 5 revolutions per minute and accelerates at the rate of 
20 revolutions per minute. Each mouse is allowed to remain on the rod in each 
trial until it falls off. Both the length of time that the mouse remains on the rod 
and the speed the rod is rotating when the mouse falls were recorded for each trial. 
10 animals were used for each type of mice at each time point. 
 
7. BV-2 and NSC-34 cell culture 
BV-2 cell is an immortalized mouse microglial cell line that exhibits the 
morphological and functional characteristics of microglia (Blasi et al., 1990; 
Bocchini et al., 1992). BV-2 microglia were cultured in DMEM supplemented 
with 2% FBS and were maintained in a humidified incubator with 5% CO2 at 37 
°C. 
NSC-34 cells, a hybrid between neuroblastoma (N18TG2) and spinal cord 
motoneurons (Cashman et al., 1992) that constitute a cell line closely related to 
motoneurons, were cultured in DMEM containing 10% FBS in a humidified 
incubator with 5% CO2 at 37 °C. 
8. CD11b siRNA transfection 
RNA interference technologies in which short double-stranded RNA 
oligonucleotides are introduced into mammalian cells or tissues have been utilized 
extensively to achieve an effective and highly specific reduction in the level of 
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messenger RNA (mRNA) expression for target genes (Novina and Sharp, 2004; 
Hannon and Rossi, 2004; Campbell and Choy, 2005). Since the silencing effect of 
siRNAs in actively replicating cells can usually peak around 96 hours after 
transfection, tapers off thereafter and is lost by 7 days (Novina et al., 2002; Tuschl 
and Borkhardt, 2002; Ullu et al., 2002). The CD11b-knockdown model was 
established by transient transfection of BV-2 cells with specific small interfering 
RNA in the current study. 
 
Materials 
SiRNA (Ambion, USA)s:  
Sense (5’Æ3’): GGAUAAAGUCACCUUCAUCtt 
Antisense (5’Æ3’): GAUGAAGGUGACUUUAUCCtt 
 
Transfection reagents:  
Oligofectamine (Invitrogen, USA) 
 
Cell culture medium:  
OPTI-MEM®I Reduced-Serum Medium (Gibco Invitrogen, USA) 
 
Positive and Negative controls: 
In each experiment, the GAPDH siRNA and the Negative Control siRNA 
served as controls. When successfully transfected, the GAPDH siRNA could 
reduce both the expression levels of mRNA and protein of GAPDH in the cells.  
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The Negative Control siRNA is a scrambled sequence that has no 
significant homology to the human, mouse, or rat genome. The Negative Control 
siRNA has no effect on the mRNA and protein levels of GAPDH and serves as a 
baseline for measuring the effects of the GAPDH siRNA. The negative control 
can be used to identify nonspecific effects generated by nonsequence-specific 
siRNA effects or cytotoxicity of transfection agents. 
A Cy3 conjugated negative control (Ambion, USA) was used to transfect 
BV-2 cells to monitor the transfection efficiency. 
8.1 Procedure 
Two ml of the cells (1×106/ml) were plated in 6-well plates for 24 hours 
before transfection. When the cells were 30-50% confluent, 10 μl 
OligofectamineTM Reagent (Invitrogen, USA) and 10 μl CD11b siRNA (Sense: 
GGAUAAAGUCACCUUCAUCTT; Antisense: 
GAUGAAGGUGACUUUAUCCTT; Ambion, USA) were mixed respectively 
with 100 μl Opti-MEM® I Reduced Serum Medium (ORSM) (Invitrogen, USA). 
The mixture was incubated for 10 minutes at room temperature. The mixture of 
100 μl diluted siRNA and 100 μl diluted OligofectamineTM was incubated for 20 
minutes at room temperature. The cells were washed once with ORSM and 800 μl 
of ORSM added into each well containing cells. After 200 μl of the prepared 
complex were gently added into each well, the cells were incubated at 37 °C in the 
CO2 incubator for 12 hours. 1ml of DMEM containing 10% FBS to the wells was 
added into each well without removing the transfection mixture. 12 hours later, 
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the mixed medium were replaced with DMEM containing 2% FBS and the cells 
were ready for assays. In all studies, the effects of the CD11b siRNA were 
compared with the negative and control siRNA (scrambled SiRNA). The 
scrambled sequence has been pretested to ensure there was no significant effect on 
expression of the target gene. Time-course studies using multiple siRNA 
concentrations were performed to determine the best experimental conditions for 
RNA analysis. Suppression of targeted mRNA was established 24 hours after 
transfection and maintained for up to 72 hours. 
Fluorescence(Cy3)-labeled scrambled siRNA (Ambion, USA) was applied 
to monitor transfection efficiency in the optimized condition. The cells were 
incubated with transfection complex of Cy3-labeled scrambled siRNA and 
Oligofectamine for 12 hours and then cells with Cy3 fluorescence were checked 
under a confocal microscope. BV-2 cells treated with the Cy3-labeled scrambled 
siRNA but without Oligofectamine were set as the control. 
Total RNA and protein were extracted respectively at 48, 72 and 96 hours 
post-transfection for CD11b mRNA and protein expression assays. LPS 
stimulation and microglial bioassays were conducted at 72 hours after 
transfection. 
8.2 Optimizing siRNA transfection conditions 
    Each experiment in optimizing siRNA transfection conditions were 
repeated three times. 
8.2.1 Amount of transfection reagent 
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The most important parameter for optimization of siRNA delivery is the 
amount of transfection agent used. Four different volumes of transfection agent 
were tested to optimize the most appropriate amount of transfection reagent by 
using 10 nM final concentration of siRNA. If acceptable levels of knockdown and 
cell viability could be obtained, no further optimization would be necessary. If 
excessive cytotoxicity or insufficient knockdown could be observed, the amount 
of siRNA or the exposure time to transfection reagent would be readjusted.  
8.2.2 Exposure time to transfection reagent. 
After determining the optimal volume of transfection agent for target 
knockdown, maximize cell viability by adjusting the time that cells were exposed 
to transfection complexes. The medium was replaced at 6 and 12 hours after 
transfection by carefully aspirating the old medium from the well and adding fresh 
medium. If acceptable levels of knockdown and cell viability could be obtained, 
no further optimization would be necessary. If excessive cytotoxicity or 
insufficient knockdown could be observed, the amount of siRNA or transfection 
reagent would be readjusted. 
8.2.3 Amount of SiRNA 
To optimize the activity of transfected siRNAs, tests of 1, 3, 10, and 30 nM 
(final concentration) siRNA were carried out to use the transfection agent quantity 
and exposure time optimized in the experiments described above. If knockdown 
levels could still not be acceptable, cell density planted for transfection would be 
readjusted. 
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8.2.4 Cell density 
For most adherent cells, the optimal confluency for transfection was 
30–80%. 
8.2.5 Test siRNA of interest 
Once an optimized protocol has been developed for BV-2 cells, all the 3 
designed siRNAs for CD11b gene were tested using the parameters established by 
these optimization experiments. 
9. Functional analysis of BV-2 microglia after silence of CD11b 
Each experiment were repeated three times. 
9.1 Cell migration analysis 
To study if microglial migration ability would be affected after the CD11b silence, 
72 hours after transfection, cells were grown in six-well plates until they achieved 
90% confluence. Using a 100 μL plastic pipette tip, we scraped 3 horizontal lines 
across the bottom of each well ('wounding'). The distance between the wound 
edges was then determined at 0, 12 and 24 hours after wounding, as a measure of 
cell migration (Guo et al., 2003). 
9.2 Measurement of Phagocytosis 
 After 72-hour transfection, the BV-2 cells were stimulated with 1 ml DMEM 
containing 1 μg LPS for 24 hours. To assay microglial phagocytotic activity, 1 
μl/ml of 0.8 μm latex beads (Sigma) was added into each well. After 2 hours the 
excess beads were removed by vigorous washing with cold PBS (pH7.4). The 
cells were fixed with 4% paraformaldehyde fixative for 20 minutes before they 
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were washed with PBS. Phagocytic cells (minimum 20 beads per cell) were 
counted as a percentage of the total number of cells in each microscopic field at 
20× magnification. 
9.3 Detection of intracellular NO production 
After 72-hour transfection, the BV-2 cells were stimulated with 1 ml 
DMEM containing 1 μg LPS for 24 hours. Then intracellular nitric oxide (NO) 
generation was monitored in the cells by using 10 AM DAF-2DA (4, 
5-diaminofluorescein diacetate, Calbiochem, USA) fluorescence as previously 
described (He et al., 2002).  
9.4 Detection of expressions of cytokines 
   Expressions of cytokines from BV-2 microglia after silence of CD11b gene 
expression have been detected using real-time PCR. Selected cytokine expressions 
have been further confirmed using Western blot. The detailed description of 
methods has been presented in next sections. 
9.5 MTS cell proliferation assay  
 This bioassess was to investigate the effect of silence of CD11b gene 
expression on LPS-induced microglial cytotoxicity over neurons. 
      Reagents 
      MTS solution (Promega, USA) 
      PMS solution (Promega, USA) 
 
 
      Procedure 
            MTS solution and PMS solution of the kit were thawn. It should 
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take approximately 10 minutes in a 37°C water bath to completely thaw the 20ml 
size of MTS solution. 2.0ml of MTS solution were removed from the amber 
reagent bottle using aseptic technique and transfered to a test tube. 100µl of PMS 
solution were added to the 2.0ml of MTS solution immediately before addition to 
the culture plate containing cells. 
            The tube was gently swirled to ensure complete mixing of the 
combined MTS/PMS solution. 20µl of the combined MTS/PMS solution were 
pipeted into each well of the 96 well assay plate containing 100µl of cells in 
culture medium and then incubated the plate for 3 hours at 37°C in a 5% CO2 
incubator. The absorbance was measured at 490nm using an ELISA plate reader. 
 
      Standard Curve  
            8×104, 4×104, 2×104, 1×104, 5×103 and 2.5×103 NSC-34 cells (100 
μl each) were separately planted into wells of a 96-well plate. After 2-hour growth 
at 37°C in a 5% CO2 incubator, 20 µl of the combined MTS/PMS solution were 
added into each of the well containing the cells. Measure the absorbance at 490nm 
3 hours later. Then a standard curve for the effect of cell numbers on absorbance 
was made for further analysis. 
      Cytotoxity of LPS stimulated CD11b knockdown BV-2 cells to NSC-34 
cells 
            1×104 NSC-34 cells were supspended in 100 μl 100% normal 
growth medium (10% FBS), 70%, 80%, 90% conditioned medium of the LPS 
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stimulated cells and incubated at 37°C in a 5% CO2 incubator for 24 and 48 hours 
before measuring the absorbance at 490nm. Finally, the cell numbers were 
calculated according to the standard curve. 
10. PCR Analysis 
10.1 Primer design 
A primer is a short synthetic oligonucleotide which is used in many 
molecular techniques from PCR to DNA sequencing. These primers are designed 
to have a sequence which is the reverse complement of a region of template or 
target DNA to which is supposed to anneal by the primer. When designing primers 
for PCR, sequencing or mutagenesis, it is often necessary to make predictions 
about these primers, for example melting temperature (Tm) and propensity to 
form dimmers with itself or other primers in the reaction. The following are some 
tips for primers design: 
Ⅰ Primers should be 17-28 bases in length. 
Ⅱ Base composition should be 50-60% (G+C) 
Ⅲ Primers should end (3´) in a G or C, or CG or GC. This presents 
“breathing” of ends and increases efficiency of primering. 
Ⅳ Tms between 55-80 °C are preferred. 
Ⅴ 3’-ends of primers should not be complementary (ie. Base pair), as 
otherwise primer dimmers will be synthesized preferentially to any other product. 
Ⅵ  Primer self-complementary (ability to form 2° structure such as 
hairpins) should be avoided. 
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Ⅶ Runs of three or more Cs or Gs at the 3’-ends of primers may promote 
mispriming at G or C-rich sequences (because of stability of annealing and should 
be avoided). 
Procedure: 
All the primers used in the present study were designed by using the 
software of Primer 3. Primer size was set as: Min 19, Opt 21 and Max 24. GC% 
was set as: Min 45, Opt 55 and Max 65. ATG position (CDS) should be checked 
as primer sequence should be in the CDS range. The primer should be as random 
as possible and the maximum Poly-X is better to be set as 3. 
      Primers used in the present study:       
Cytokines Sequence (5'-3') Length (bp)b 
CD11b-FW CTCCGGTAGCATCAACAACAT 169 
CD11b-RV TGATCTTGGGCTAGGGTTTCT  
TGF-β1-FW TGACGTCACTGGAGTTGTACGG 170 
TGF-β1-RV GGTTCATGTCATGGATGGTGC  
IL-10-FW GGTTGCCAAGCCTTATCGGA 191 
IL-10-RV ACCTGCTCCACTGCCTTGCT  
TNF-α-FW CATCTTCTCAAAATTCGAGTGACAA 175 
TNF-α-RV TGGGAGTAGACAAGGTACAACCC  
IL-1β-FW CAACCAACAAGTGATATTCTCCATG 152 
IL-1β-RV GATCCACACTCTCCAGCTGCA  
IL-4-FW ACAGGAGAAGGGACGCCAT 170 
IL-4-RV GAAGCCCTACAGACGAGCTCA  
IL-6-FW GGATACCACTCCCAACAGACC 162 
IL-6-RV TCCAGTTTGGTAGCATCCATC  
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iNOS-FW AGGACCTCTGGAAGAGCAGTC 165 
iNOS-RV AGGCTGCCCTACTCTTGAGAC  
GADPH-FW AACTTTGGCATTGTGGAAGG 172 
GADPH-RV ACACATTGGGGGTAGGAACA  
10.2 Sample preparation 
      The lumbar cord segments were taken out from NFL-/- and C57BL/6 mice 
under deep anesthesia and immediately dipped into a liquid nitrogen container and 
kept therein at -80°C. The CD11b siRNA transfected BV-2 and the control cells 
were cultured in 5% CO2 incubator at 37°C. 
10.3 RNA Isolation 
10.3.1 Trizol reagent (for the lumbar cord segments of NFL-/- and C57BL/6 
mice). 
Reagents: 
Trizol (Invitrogen, USA) 
Chloroform 
Isopropyl alcohol 
75% Ethanol (in DEPC-treated water) 
RNase-free water (Qiagen, USA)  
Procedure: 
HOMOGENIZATION 
The tissue samples were homogenized in 1ml of TRIZOL Reagent per 
50-100 mg of tissue using a homogenizer (Ultra-turrax T25 basic). 
PHASE SEPARATION 
The homogenized samples were incubated for 5 minutes at 15 to 30°C to 
permit the complete dissociation of nucleoprotein complexes. 0.2 ml of 
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chloroform was added into 1 ml of TRIZOL Reagent. The sample tubes were 
capped securely and shaked vigorously by hand for 15 seconds. The tubes were 
incubated at room temperature for 2 to 3 minutes. The samples were centrifuged at 
10,000× g for 15 minutes at 4°C. Following centrifugation, the mixture was 
separated into a lower red, phenol-chloroform phase, an interphase, and a 
colorless upper aqueous phase. RNA remained exclusively in the aqueous phase. 
The volume of the aqueous phase was about 60% of the volume of TRIZOL 
Reagent used for homogenization. 
RNA PRECIPITATION 
The aqueous phase was transferred to a fresh tube, and the organic phase 
was saved if isolation of DNA or protein is desired. The RNA was precipitated 
from the aqueous phase by mixing with isopropyl alcohol. 0.5 ml of isopropyl 
alcohol per 1 ml of TRIZOL Reagent was used for the initial homogenization. The 
samples were incubated at room temperature for 10 minutes and centrifuged at 
10,000 × g for 10 minutes at 4°C. The RNA precipitate, often invisible before 
centrifugation, was formed a gel-like pellet on the side and bottom of the tube. 
RNA WASH 
The supernatant was removed. The RNA pellet was washed once with 75% 
ethanol by adding at least 1 ml of 75% ethanol per 1 ml of TRIZOL Reagent used 
for the initial homogenization. The sample was mixed by vortexing and 
centrifuged at 7,500 × g for 5 minutes at 4°C. 
REDISSOLVING THE RNA 
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At the end of the procedure, the RNA pellet was briefly dried (air-dry or 
vacuum-dry for 5 minutes). It is important not to dry the RNA by centrifugation 
under vacuum and not to let the RNA pellet dry completely as this will greatly 
decrease its solubility. The RNA samples were then partially dissolved at an 
A260/280 ratio < 1.6. The RNA was dissolved in RNase-free water by passing the 
solution a few times through a pipette tip, and incubating for 10 minutes at 
60°C.The concentration and purity of the extracted RNA were evaluated by 
spectrophotometric absorbance readings at 260nm and 280nm (Eppendorf 
Biophotometer, USA). 






RNeasy mini spin columns 
RNase-free water 
Procedures 
β-Mercaptoethanol (β-ME) was added to Buffer RLT before use. β-ME is 
toxic and care must be taken to dispense in a fume hood. 10 μl β-ME per 1 ml 
Buffer RLT were added. After the cells were washed 3 times with PBS, the buffer 
RLT containing β-ME was added to the cells. The cells were scraped down by 
using cell scraper and then were transferred to 2ml size vials. Use 31G syringe to 
suck in and out repeatly 10 times to homogenize the cells.     
One volume of 70% ethanol was added to the homogenized lysate, and 
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mixed well by pipetting. If some lysate was lost during homogenization, the 
volume of ethanol would be adjusted accordingly. Up to 700 μl of the sample 
including any precipitate that may have formed were transfered to an RNeasy spin 
column which was placed in a 2 ml collection tube. The lid was closed gently and 
the column was centrifuged for 15 seconds at 13,000 rpm. The flow-through was 
discarded. If the sample volume exceeded 700 μl, successive aliquots were 
centrifuged in the same RNeasy spin column. The flow-through was discarded 
after each centrifugation. 700 μl Buffer RW1 was added to the RNeasy spin 
column and centrifuged for 15 seconds at 13,000 rpm to wash the spin column 
membrane. The flow-through was discarded. After the centrifugation, the RNeasy 
spin column was carefully removed from the collection tube so that the column 
did not contact with the flow-through. Be sure to empty the collection tube 
completely. 
500 μl Buffer RPE were added to the RNeasy spin column and centrifuged 
for 15 seconds at 13,000 rpm to wash the spin column membrane. The 
flow-through was discarded. 500 μl Buffer RPE was added to the RNeasy spin 
column and centrifuged for 2 minutes at 13,000 rpm to wash the spin column 
membrane. The long centrifugation could dry the spin column membrane to 
ensure that no ethanol was carried over during RNA elution. Residual ethanol may 
interfere with downstream reactions. The RNeasy spin column was placed in a 
new 2 ml collection tube, and the old collection tube with the flow-through was 
discarded. The RNeasy spin column was centrifuged at the full speed for 1 minute. 
MATERIALS AND METHODS                              66
The RNeasy spin column was placed in a new 1.5 ml collection tube. 30 μl 
RNase-free water was added directly to the spin column membrane and 
centrifuged for 1 minute at 13,000 rpm to elute the RNA. The concentration and 
purity of the extracted RNA were evaluated by spectrophotometric absorbance 
readings at 260nm and 280nm (Eppendorf Biophotometer, USA). 
10.4 Real time quantitative reverse transcription combined with polymerase 
chain reaction (qRT-PCR) 
10.4.1 cDNA synthesis 
Reagents: 
DEPC H2O 
Oligo(dT) 15 Primer (Promega, USA) 
M-MLV RT 5X Buffer (Promega, USA) 
rRNasin ® RNase inhibitor (Promega, USA) 
M-MLV Reverse Transcriptase (Promega, USA) 
dNTP Mix 10mM (Promega, USA) 
Procedure: 
Two μg RNA sample were mixed with 2 μl oligo(dT) 15 primer and DEPC 
H2O to make a final volume of 15 μl. After incubation at 70°C for 5 min, the vials 
containing the mixture solution were immediately transferred onto ice to cool 
down for 5 minutes. 
Five μl M-MLV RT 5X Buffer were mixed with 1.25 μl dNTP Mix, 0.675 
μl RNase inhibitor and 1 μl M-MLV Reverse Transcriptase. The mixture solution 
containing RNA sample was transferred into a new vial and incubated at 42°C for 
1 hour, following by 5-minute incubation at 90°C. 
10.4.2 Real Time qRT-PCR 
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Real time quantitative PCR is a new approach in PCR-technology. It is 
much faster and more reliable than other semi-quantitative PCR-techniques, such 
as competitive PCR and picture-analysis after eletrophoresis. The SYBR-Green 
method uses SYBR-Green I® as a fluorescent dye which intercalates specifically 
with dsDNA during the extension phase of the PCR. For quantification of the 
starting amount of template DNA, the threshold cycle (Ct) of each sample is 





RNase free water 
QuantiTect TM SYBR® Green PCR master Mix (Qiagen, USA) 
Procedure 
The qRT-PCR was performed using a LightCycler instrument (Roche, 
Mannheim, Germany) for 45 cycles of denaturation at 95°C for 10 seconds, 
annealing at 55°C for 5 seconds and elongation at 72°C for 8 seconds. Each 
reverse transcriptase product (1 µl) was amplified in the reaction mixture (10 µl) 
containing 3 µl LightCycler-FastStart DNA MasterPLUS SYBR Green I mix 
(Roche), 5 µl of RNase free water and 0.5µl of each primers (10µM). The level of 
specific mRNA was quantified, expressed as Ct, the cycle number at which the 
LightCycler System detected the upstroke of the exponential phase of PCR 
product accumulation, and normalized by the level of GAPDH or ß-actin 
expression in each individual sample (Fields and Casey, 1997). 
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10.4.3 Detection of PCR products 
Materials 
1.5% agarose gel: Agarose (Bio-Rad)                          1.5g                
Ethium Bromide solution (Bio-Rad)                           10μl                
TAE buffer (NUMI)                                      100ml   
 
      Procedure 
PCR products were run on agarose gel using electrophoresis. 1.5% agarose 
gel was prepared by heating agarose in the TAE buffer (0.04M Tris-base, 0.001M 
EDTA, Glacial acetic acid, pH7.8). Ethidium bromide was added into the gel. The 
gel was cooled and poured onto a gel tray and allowed to solidify. 10μl of each 
RT-PCR product was loaded in each lane of the gel and electrophoresed at 110V 
for 30 minutes in TAE buffer along with 650ng of 100bp DNA ladder (Promega). 
Analysis of RT-PCR bands 
The PCR bands were visualized with an ultraviolet trans-illuminator and 
photographed (Polaroid). The 100bp DNA ladder was used to determine the size 
of the amplified DNA from 100-1500bp. 
All photographed PCR products were scanned and analyzed using NIH 
Image software. For respective samples, the PCR product values were normalized 
to the ACTIN PCR product value. 
11. Western Blot 
Materials and reagents 
M-PER® Mammalian Protein Extraction Reagent (#78501, Pierce, USA) 
HaltTM.Protease Inhibitor Cocktail (Pierce, USA) 
EDTA solution 100X (Pierce, USA) 
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Bio-Rad Protein Assay (Dye reagent Concentrate) (BioRad, USA) 
30% Acrylamide/Bis Solution 29:1 (3.3% C) (Bio-Rad, USA) 
Ammonium persulfate (Bio-Rad, USA) 
Bio-Rad Protein Assay Standard Lyophilized Bovine Serum (Bio-Rad, 
USA) 
Bio-Rad Protein Assay (Dye reagent Concentrate) (Bio-Rad, USA) 
N,N’-methylene bisacrylamide N,N,N,N-Tetramethylenediamine (TEMED) 
(Bio-Rad, USA) 
10% Tween 20 solution (Bio-Rad, USA) 
10% (W/V) SDS solution (1st Base Singapore) 
Tris, Electrophoresis Purity Reagent Tris(hydroxymethayl)-aminomethane 
(Bio-Rad, USA) 
Glycine, Electrophoresis purity reagent (Bio-Rad, USA) 
1.5 M Tris-HCL Buffer pH 8.8 (Bio-Rad, USA) 
0.5 M Tris-HCL Buffer pH 6.8 (Bio-Rad, USA) 
Blotting grade Blocker Non-Fat Dry Milk 
 
1X SDS/Glycine Electrophoresis Buffer: 








800ml distilled water 
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Extra Thick Blot Paper Protean® XL Size (Bio-Rad, USA) 
Immun-Blot PVDF Membrane 20X20 cm (Bio-Rad, USA) 
Supersignal® West Dura Extended Duration Substrate (Substrate A and B) 
(Pierce, USA) 
CL-XPosureTM Film 18X24 cm Clear Blue X-Ray film (Pierce, USA) 





Antibody Cocentration Company 
Anti-IL-1β 1:1000 Chemicon (USA) 
Anti-TNF-α 1:1000 Chemicon (USA) 
Anti-IL-6 1:1000 Chemicon (USA) 
Anti-iNOS 1:1000 Chemicon (USA) 
Anti-MCP-1 1:1000 Chemicon (USA) 
Anti-ERK 1:1000 Cell Signaling (USA) 
Anti-JNK 1:1000 Cell Signaling (USA) 
Anti-P38 1:1000 Cell Signaling (USA) 
Anti-Pho-ERK 1:1000 Cell Signaling (USA) 
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Anti-Pho-JNK 1:1000 Cell Signaling (USA) 
Anti-Pho-P38 1:1000 Cell Signaling (USA) 
Anti-rabbit(HRP) 1:2000 Cell Signaling(USA) 
 
      Procedure: 
      Protein extraction 
Culture medium was carefully removed from the adherent cells and the 
cells were washed with PBS twice. Add appropriate amount of Lysis buffer 
containing protease inhibitor and EDTA solution to the flasks or wells and shake 
gently for 5 minutes. The lysate was collected and transferred to a microcentrifuge 
tube. The samples were cententrifuged at 14,000×g for 10 minutes and the 
supernatant was transferred to a new tube for further analysis.     
Aliquate the supernatant into small vials and use 1 vial for protein 
concentration analysis and the others for protein denature.  
            Protein denature 
    The temperature of a heat block was adjusted to 95°C. 1 volume of loading 
dye (6×) to 5 volumes of protein were added and then heated for 10 minutes at 
95°C. The samples were stored at -20°C. 
Protein concentration analysis 
    A standard curve for protein concentration was made by using Bio-Rad 
Protein Assay Standard Lyophilized Bovine Serum (1.25mg/ml). The standard 
protein was diluted with distilled water into 0.5, 0.25, 0.125, 0.0625 and 0.03125 
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mg/ml in wells of 96-well plate. The final volume was 10 μl for each 
concentration. 200 μl of diluted protein dye (1:5) were added into each well 
containing the standard protein. The mixture was incubated at room temperature 
for 5 minutes and then measured the absorbance at 595nm.  
    Protein samples were diluted into 5 different concentrations and 
incubated with protein dye for 5 minutes. An appropriate concentration of the 
samples (whose color density was close to that of the 0.125 standard protein with 
protein dye) was selected to measurement of the absorbance at 595 nm. The 
concentrations of the samples then were calculated according to the standard 
curve. 
Gel Preparition 
Separating Gel (10ml) 
                                 4%                       10%  
      H2O                         2.30 ml                    4.0 ml 
      30% acrylamide mix       1.35 ml                 3.3 ml 
      1.5 M Tris (pH 8.8)             1.25 ml                    2.5 ml 
      10% SDS                     0.05 ml                    0.1 ml 
      10% ammonium persulfate       0.05 ml         0.1 ml 
      TEMED                     0.004 ml                  0.004 ml 
 
 4% separating gel was prepared for iNOS and 10% for the other proteins. The 
separating gel was injected slowly into the gap of two pieces of glasses 
immediately after adding TEMED. Then 100% alcohol was added to fill up with 
the glasses to get rid of any bubbles. Keep the gel at room temperature for 20 
minutes until it becomes a solid. 
4% Stacking gel (5ml) 
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H2O                                                   3.4 ml 
30% acrylamide mix                                     0.83 ml 
1.5 M Tris (PH 8.8)                  0.63 ml 
10% SDS                                              0.05 ml 
10% ammonium persulfate             0.05 ml 
TEMED             0.005 ml 
 
 The alcohol was removed and the stacking gel was injected slowly into the 
gap immediately after adding TEMED. A 15-well comb was inserted into the 
stacking gel immediately after adding the gel solution. The gel was kept at room 
temperature for 20 minutes until it became solid. 
 
Electrophoresis 
1×SDS/Glycine electrophoresis buffer. 
Tris Base                                           1.51g/litre 
SDS                                                 5g/litre 
Glycine                                             7.2g/litre 
 
 The glasses containing the gels were transfer into an electrophoresis tank 
(Bio-Rad, USA). The combs were removed from the gels and 200 ml 
electrophoresis buffer were added into the tank. The glass gap should also be 
filled with electrophoresis buffer. 5 μl Precision Plus Protein TM Standards (Dual 
Color) and 10 μg of denatured protein samples were added into the wells 
respectively. Then start electrophoresis at 120 V for 100 minutes. 
Semi-dry transferring 
Transferring buffer (2 liters) 
Tris                                                    3.03 g 
Glycine                     14.4g 
Methanol                                              l 200ml  
MATERIALS AND METHODS                              74
Water                                                  800ml 
 
      Six filter papers (for 2 gels) with transfer buffer for 30 mins were 
incubated. 2 PVDF membranes were incubated with methanol for 10 seconds and 
then with transfer buffer for 15 minutes. The gels were separated from the glasses 
and kept into transfer buffer. From the plate of the Semi-dry transfer machine, 1 
filter paper, 1 membrane, 1gel, 2 filter papers were placed in sequence and then 
the proteins were semi-dry transferred at 20V for 1 (for ERK, JNK, P38, 
Phospho-ERK, Phospho-JNK and Phospho-P38) or 2 (for CD11b) hours.  
 
Immunoblotting 
0.1% TBS-Tween (1 liter)  
Water                                               1000 ml 
10% Tween                                             10 ml 
 
5% milk (50 ml)  
0.1% TBS-Tween                                     50 ml 
Non-fat dry milk                                         2.5g 
 
   The membranes were incubated with 5% milk on a shaker at room 
temperature for 1 hour and then washed with 0.1% TBS-Tween twice. The 
membranes with TBS-Tween diluted primary antibodies were incubated on a 
shaker at 4°C overnight. The membranes were washed with TBS-Tween on a 
shaker at room temperature for 3 times of 15 minutes each and then incubated 
with TBS-Tween diluted HRP-secondary antibodies on a shaker for 1 hour at 
room temperature. 
The membranes were washed with TBS-Tween on a shaker at room 
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temperature for 3 times of 15 minutes each. The mixture of equal volume of 
substrates A and B was incubated for 5 minutes at room temperature. The 
substrate mixture then was added on the membranes and incubated for 1 minute. 
The excess detection reagents were drained off by holding the membrane 
vertically with forceps and touching the edge against a tissue paper. The 
membrane with its protein side up was gently placed on a piece of plastic sheet. 
The membrane was covered with another piece of plastic sheet. After the air 
bubbles were gently smoothed out, the membrane was transferred to a dark box 
for X-Ray exposure. The signal was detected using a film developer after the 
exposure of the film to x-ray. The membranes were exposed to x-ray for 10 
seconds and re-exposed according to the intensity of signals. If the signals were 
too strong (background too high), exposure time (e.g. 1-5 seconds) was reduced 
accordingly. If the signals are too weak, exposure time (e.g. 5-20 minutes or 
overnight) was increased. The membranes could also be re-incubated overnight 
with 1x HRP-conjugated streptavidin and re-detected on the second day. The 
membrane could be kept at –80°C for future references.  
12. Statistical analysis 
      All the experiments were repeated at least in triplicate for statistical 
purpose, and where appropriate, the data were presented as mean and standard 
deviation (SD). All quantitative data were statistically evaluated using the 
Student’s t-test. The level of significance was set at p<0.05. 
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1. Neuropathogenesis in early age of NFL-/- mice 
1.1 Redistribution of NFH and NFM from processes to perikarya of neurons 
in the ventral horn of the spinal cord 
Apparent NFH protein aggregates were observed in the lumbar cord 
segments of NFL-/- mice (Fig. 1 B and D). There was a marked shift in the 
distribution of NFH in neurons in the ventral horn of the lumbar cord segments in 
NFL-/- mice. In normal neurons of C57BL/6 mice, the perikarya of neurons were 
almost negatively stained for both NFH and NFM while the neuronal processes 
clearly showed positive staining (Fig.2 A and Fig. 3 A). In the neurons of NFL-/- 
mice, a drastic diminution in NFH immunostaining (Fig.2 B) in the neuronal 
processes was observed in the NFL-/- mice but only slightly decrease in NFM 
immunostaining (Fig.3 B) in the neuronal processes. The NFH protein appeared to 
accumulate locally in the perikarya and axons of neurons and formed aggregates 
(Fig.2 B). From electron micrographs, the accumulation of the proteins formed a 
large amorphous area in the perikarya of neurons and the cellular organelles were 


















Fig. 1 Immunohistochemistry of NFH in the lumbar cord segments 
The Lumbar cord segments from C57BL/6 (A and C) and NFL-/- (B and D) mice 
were stained with antibody against NFH.  Protein aggregation densely labeled 
with NFH antibody were observed mainly in large neurons of the ventral horn of 
























                                          
Fig. 2 Protein aggregates of NFH in neurons in the ventral horn of the 
lumbar cord segments  
Immunohistochemistry shows that NFH was mainly distributed in the processes of 
neurons in C57BL/6 mice (A). However, NFH appeared to diminish from most 
neuronal processes and accumulates in the cell bodies (arrow) and a few 
processes (arrow head) of neurons in NFL-/- mice (B). Electron micrographs 
showed a normal motoneuron (C) in the lumbar cord segment in the C57BL/6 
mouse and an aggregate-bearing motoneuron (D) in a NFL-/- mouse. The protein 
aggregation (*) was shown as a large amorphous area and the crowding of 
cellular organelles can be noted as the result of the aggregate occupying a 
considerable area in the neuronal cell body in a NFL-/- mouse. Scale bar, 50μm 
(A-B,) and 5 μm (C-D). 









Fig. 3 Protein aggregates of NFM in neurons in the ventral horn of the 
lumbar cord segments 
Although striking NFM positive protein accumulation was found in the cytoplasms 
of the motoneurons in the spinal cord of NFL-/- mice (B),the NFM positive 
processes were observed clearly in the spinal cord of the NFL-/- mice in 
comparison with that of C57BL.6 mice (A). Scale bar, 50μm. 
 
1.2 Silver staining of degenerative neurons in NFL-/- mice. 
While the abnormal protein aggregates of NFH and NFM were observed 
by immunostaining the two proteins, degenerating neurons were further confirmed 
by silver staining in the lumbar cord segments of NFL-/- mice. The degenerating 
neurons were stainned in dark brown color in NFL-/- mice (Fig. 4 B), but the 
normal neurons were in light brown color in C57BL/6 mice (Fig. 4 A).  
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Fig. 4 Silver staining degenerating neurons 
The degenerating neurons were stained in dark brown color (arrow) in NFL-/- 
mice (B), but the normal neurons were in light brown color (arrow) in C57BL/6 
mice (A).  
 
1.3 Less motoneuron cell number 
The results of counting of large cells in the ventral horn from Nissl stained 
sections of the lumbar cord of NFL-/- and C57BL/6 mice showed that the number 
of large neurons in the NFL-/- mice was 20% less than that in the C57BL/6 mice 
in all age groups but no further neuronal loss occurred until 6 months of age (Fig. 
5). There was no significant difference in the motoneuron numbers among the 
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Fig. 5 Motoneuron number  
The numbers of large neurons with nucleus in the ventral horn of the 
lumbar cord segments were counted in Nissl stained sections of the lumbar cord 
segments in C57BL/6 (A) and NFL-/- mice (B). The number of large neurons in 
the lumbar cord segments of NFL-/- mice was about 20% less than that of 
C57BL/6 mice at age of 1 month and there was no further neuronal loss at least 
till the age of 6 months (C) (* p<0.05). The photomicrographs were taken from the 
same level of the lumbar cord segment under the same magnification from the two 
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1.4 Smaller size of spinal cord 
As shown in Figure 6, the lumbar cord segments of NFL-/- and C57BL/6 
mice were measured by 7 lines. The Line 1 and 2 were the horizontal and vertical 
diameters of the lumbar cord sections. The average length of Line 3 or 4 
represented the length of the longest line from the central canal to the dorsal horn 
(L3) or ventral horn (L4) respectively. The average length of Lines 5, 6 and 7 
(indicated as AL(567)) were measured to indicate the thickness of the white matter. 
The values of the various measurements are shown in Figure 6. These results 
have indicated that not only the whole spinal cord size of NFL-/- mice was smaller 
than that of C57BL/6 mice, but also specifically the white matter of NFL-/- 


























Fig.6 Spinal cord size  
The various parameters (A) were measured for the NFL-/- and C57BL/6 mice 
from 1 to 6 months age. The diameter of the lumbar segment of the spinal cord 
was obviously smaller in the NFL-/- mouse than that in the C57BL/6 mouse (B, C). 
The longest length of the grey matter in both the ventral (D) or dorsal (E) horn in 
the NFL-/- mice was smaller than that in the C57BL/6 mice. The average 
thickness of the white matter (F) of the spinal cord of the NFL-/- mice was also 
thinner than that of the contral. The photographs were taken from the same level 
of the lumbar cord segments of two types of mice under the same magnification. 
The decreases in the above measurements between two types of mice were all 
significant (P<0.05). Scale bar, 500 μm. 
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1.5 Motofunction of NFL-/- mice 
The Rota-Rod test showed that there were no significant difference in the 
stay-on time between the NFL-/- and C57BL/6 mice from ages of 10-18 weeks 
(Fig. 7). This suggests that there was no obvious motor dysfunction in the early 
age of NFL-/- mice, although significant abnormal protein aggregates were found 














Fig. 7 Rota-Rod test 
Motofunction of NFL-/- and C57BL/6 mice were measured by Rota-Rod test from 
the age of 10 to 18 weeks. There was no significant difference in the stay-on time 
between the two types of mice. 
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1.6 No obvious glial activation in NFL-/- mice 
1.6.1 No obvious difference in the number of CD11b positive cells 
Analysis of CD11b stained sections showed no obvious difference in the 
number of CD11b positive microglial cells in the ventral horn of the lumbar cord 
segments between NFL-/- and C57BL/6 mice from 1 to 6 months of age (Fig. 8 
and Fig 9 A-F), in comparison with the significant increase in the number of 
microglial cells in the ventral horn of the lumbar cord segments after sciatic nerve 
transection in both mice (Fig. 15 C and Fig. 14 C). Furthermore, there was no 
sign of microglia clustering around any of the large aggregate-bearing neurons in 
the ventral horn of the lumbar cord segments in NFL-/- mice (Fig. 9 B, D, F), 
when compared with the drastic microglial migration toward axotomized neurons 










Fig. 8 The number of microglial cells in NFL-/- and C57BL/6 mice  
There was no obvious difference in the number of microglial cells in the ventral 
horn of the lumbar cord segments between NFL-/- and C57BL/6 mice. 














Fig. 9 Microglial activations 
Immunostaining of CD11b in the ventral horn of the lumbar cord segments in 
C57BL/6 (A, C, E,) and NFL-/- mice (B, D, F,) at 1 (A&B), 3 (C&D) and 6 (E&F) 
months of age. CD11b immunohistological staining was obviously less intense in 
the cord sections of NFL-/- mice in all age groups, suggesting a down-regulation 
of microglial CR3 subunit. Photos A-F were taken at the same magnification. 
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1.6.2 No obvious difference in GFAP positive cells 
There was no obvious difference in GFAP staining and change in the morphology 
of astrocytes between the two types of mice as shown by the GFAP stained 
sections of all the age groups (Fig. 10 A, C, E for C57BL/6 and B, D, F for 


























Fig. 10 Glial activations 
Immunostaining of GFAP in the ventral horn of the lumbar cord segments in 
C57BL/6 (A, C, E) and NFL-/- mice (B, D, F) at 1 (A&B), 3 (C&D) and 6 (E&F) 
months of age. There was no obvious difference in the intensity of GFAP 
immunohistological staining in the cord sections of NFL-/- mice in all age groups. 
Scale bar, 100 μm. 
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2. Downregulation of CD11b expression in microglia 
2.1 Down-regulation of CD11b expression in microglia 
A marked decrease in CD11b staining intensity was observed in microglial 
cells in the ventral horn of the lumbar cord segments of NFL-/- mice in 
comparison with that in the C57BL/6 mice (Fig. 9 A-F). This was further 
confirmed by significant decreases in the number of pixels with CD11b positive 
staining (Fig. 11) and also obvious mRNA expression decreases of CD11b in the 
lumbar cord segments of NFL-/- mice from 1 to 6 months age (Fig. 12), 
suggesting a down-regulation of microglial CD11b expression. It is worth to note 
that the down-regulation of CD11b mRNA was the most significant at the age of 1 
month but returned slightly toward the expression levels in the normal controls at 



















Fig. 11 Measurement of positive CD11b staining pixels  
A significant decrease was detected in the number of CD11b positive pixels in the 
digital image of the ventral horn of the lumbar cord segments in NFL-/- mice, 
compared with that in C57BL/6 mice. A trend of increase in the number of CD11b 
positive pixels has been revealed in older ages. All photographs measured were 

















Fig. 12 Comparison of CD11b mRNA expressions in the lumbar cord 
segments between C57BL/6 and NFL-/- mice by Real-Time PCR.  
The CD11b mRNA expressions in NFL-/- mice respectively were 42.2%, 58.8% 
and 79.9% of those in the corresponding controls of C57BL/6 mice. (**p<0.01) 
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2.2 Similar CD 11b staining in peripheral macrophages 
There was no obvious difference in CD11b staining intensity in 
macrophages of the livers and spleens between the NFL-/- (Fig. 13 A) and 
C57BL/6 (Fig. 13 B) mice, indicating that the down-regulation of CR3 alpha 

















Fig. 13 Immunohistochemistry of CD11b in the spleen in NFL-/- mice (A) and 
C57BL/6 (B) 
Immunostaining of CD11b showed that there was no obvious difference in CD11b 
expression in peripheral macrophages in the liver between C57BL/6 and NFL-/- 
mice. 
3. Glial activation ability towards axotomy 
3.1 Microglial reaction 
3.1.1 Microglia in NFL-/- and C57BL/6 mice could swiftly react to axotomy  
After transection of the right sciatic nerve, a marked increase in CD11b and 
staining intensity was observed in the ipsilateral dorsal and ventral horns of the 
A B 
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lumbar cord segments in the NFL-/- (Fig. 14) and C57BL/6 (Fig. 15) mice as 
early as 1 day after operation. The staining was the most intense at 5 days. The 
quatitative data are presented in Figure 17. 
 
Fig. 14 Microglial reaction after sciatic nerve cut in NFL-/- mice  
After unilateral sciatic nerve cut at midthigh level, a stronger CD11b staining was 
seen in the ipsilateral ventral horns (A-C) , compared to the unlesioned side (D-E) 
of the L4 cord segments in the NFL-/- mice. From 1 day (A) to 5 days (C) after 
operation, the staining intensity was obviously increased. Scale bar, 100 μm. 
 
 













Fig. 15 Microglial reaction after sciatic nerve cut in C57BL/6 mice   
After unilateral sciatic nerve cut at midthigh  level, a stronger CD11b staining 
was seen in the ipsilateral ventral horns (A-C) , comparing to the unlesioned side 
(D-E) of the L4 cord segments in the C57BL/6 mice. From 1 day (A) to 5 days (C) 
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3.1.2 Microglia in NFL-/- and C57BL/6 mice could migrate towards and 
enwrap axotomized motoneurons  
CD11b positive cells could closely enwrap the injured motoneurons in both 
types of mice at 5 days after operation (Fig. 16).  
3.1.3 Microglia from NFL-/- mice showed retardation in morphological 
transformation after axotomy  
It was important to note that activated microglia in the C57BL/6 mice 
showed more obvious withdrawal of their processes leaving clearer space between 
CD11b positive cells after sciatic nerve transection ((Fig. 16 A), suggesting 
microglia from C57BL/6 mice may possess a better ability to transform towards 







Fig. 16 Microglial activations to axotomy 
Immunostaining of CD11b in the ventral horn of the lumbar cord segments in 
C57BL/6 (A) and NFL-/- mice (B). Five days after unilateral sciatic nerve cut at 
mid-thigh level, activated microglia showed more obvious withdrawal of their 
processes leaving clearer space between CD11b positive cells, suggesting a better 
ability in transformation towards the amoeboid type in C57BL/6 mice, compared 
to that in NFL-/- mice. Scale bar, 100 μm. 
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 The significant increase in CD11b staining in both mice was also confirmed 
by using Image-Pro Plus software to measure the number of pixels with CD11b 
positive staining (Fig. 17). It is important to note that at 5 days after operation, 
microglia from C57BL/6 mice had transformed into cells with less processes and 
rounder cell bodies (Fig 16 A), however, microglia from NFL-/- mice still showed 
numerous processes (Fig 16 B) which would therefore occupy more CD11b 










Fig 17 Positive CD-11b staining pixels measurement after nerve injury  
At day 1, 3, and 5 after right sciatic nerve transection, the number of CD11b 
positive pixels increased gradually in the ventral horn of the lumbar cord in the 
lesioned side. There was no obvious time difference in the CD11b upregulation 
between NFL-/- and C57BL/6 mice after sciatic nerve transection. All the CD11b 
staining photographs were taken under the same condition. (* *p<0.01) 
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3.2 Astrocytes could also react to axotomy 
 After the sciatic transection, astrocyte reaction monitored by GFAP staining 
showed a slight delay in both mice. The increase in GFAP staining was evident at 
5 days after operation and the staining intensity between the two types of mice 











Fig. 18 Activation of astrocytes after sciatic nerve cut in NFL-/- mice 
From 1 to 3 days after unilateral sciatic nerve cut, there was no obvious 
activation of astrocytes in the ipsilateral ventral horn. However,s five days after 
unilateral sciatic nerve cut at mid-thigh level, a stronger GFAP staining was 
observed (C), compared to the unlesioned side (E) at the L4 cord segment in the 
NFL-/- and C57BL/6 mice. All the photos were taken at the same magnification. 
Scale bar, 100 μm. 
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4. Inducible Iba-1 expression in CD11b positive microglia 
Micrographs showed that not all CD11b positive microglia have been 
doubly stained with the Iba-1 antibody but all Iba-1 positive microglia were 
CD11b positive in C57BL/6 mice. However, almost all CD11b positive microglia 
were stained positively for Iba-1 in NFL-/- mice (Fig. 19). In both C57BL/6 mice 
(Fig. 19B) and NFL-/- mice (Fig. 20), after sciatic nerve section, most CD11b and 
Iba-1 positive cells were doubly stained, suggesting that Iba-1 expression could be 




Fig. 19 Double labeling of CD11b (red) and Iba-1 (green) in the lumbar cord 
segments  
In C57BL/6 mice, some CD11b positive microglia were not double labeled with 
the Iba-1 antibody (arrows in A) but all Iba-1 positive microglia were CD11b 
positive (yellow). After sciatic nerve section in C57BL/6 mice, the CD11b and 
Iba-1 positive cells were well colocalized (B), suggesting that Iba-1 expression 
could be induced in some CD11b positive cells. Most CD11b positive microglia 
were stained with Iba-1 antibody in NFL-/- mice (C). Scale bar, 50 μm. 
 






Fig. 20 Double labeling of CD11b (red) and Iba-1 (green) after sciatic nerve 
cut in NFL-/- mice 
Five days after sciatic nerve section in NFL-/- mice, the CD11b and Iba-1 positive 
cells were well colocalized. A: Iba-1staining B: CD11b staining. C: Merged 
image of Iba-1 and CD11b staining. Scale bar, 100 μm. 
 
5. Differential mRNA expressions in cytokines in the spinal cord  
Real-time PCR analysis showed that there was no obvious difference in 
the mRNA expression levels of TGF-β1, IL-10 and TNF-α in the lumbar cord 
segments between the two types of mice at the different time intervals. However, 
the results showed a significant increase in IL-1β mRNA expression and a 
significant decrease in IL-4 mRNA level in NFL-/- mice compared with those in 
C57BL/6 mice (Fig. 21 and 22), suggesting possible connections between 












Fig. 21 Relative quantification of TGF-β1, IL-10, and TNF-α mRNA levels in 
the lumbar cord segments of 1-, 3-, and 6-month old C57BL/6 and NFL-/- 
mice  
The data were normalized according to the endogenous reference gene β-actin 
and presented as the fold of changes in mRNA expression relative to the calibrator, 
the amount of TGF-β1 mRNA, in 3-month old C57BL/6 mice. There were no 
obvious differences in mRNA expression levels for TGF-β1, IL-10, and TNF-α 
between the two types of mice in the different age groups. Results are presented as 
the fold of changes in mRNA expression relative to the amount of TGF-β1 mRNA 






Fig. 22 Differential mRNA expressions of IL-1β and Il-4 in the lumbar cord 
segments of 1-, 3-, and 6-month old C57BL/6 and NFL-/- mice 
The data were normalized according to the endogenous reference gene β-actin 
and presented as the fold of changes in mRNA expression. From age of 1 month to 
6 months, NFL-/- mice possessed an obvious higher of Il-1 β (A) but lower of Il-4 
(B)mRNA expressions than those in C57BL/6 mice. (* p<0.05, * *p<0.01) 
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6. Functional alteration in microglia after siRNA-mediated CD11b gene 
suppression in vitro  
6.1 Effectiveness of CD11b siRNA transfection 
6.1.1 Transfection efficiency 
According to the mechanism of RNAi triggered by siRNA (Fig. 23), the 
present study explored transient siRNA transfection to specifically knockdown 
CD11b gene in BV-2 cells. Characterization of siRNA uptake was conducted by 
transfecting BV-2 cells with Cy3-conjugated, nonspecific control siRNA. The 
observation by fluorescence microscopy after 12-hour transfection has indicated 
high transfection efficiency, with nearly all of the transfected cells showing 
cytoplasmic perinuclear fluorescence (Fig. 24 A-C).  There were no Cy3 positive 
cells after the cells were treated with Cy3-conjugated siRNA but in the absence of 
























Fig. 23 RNAi triggered by siRNAs 
In non-mammalian systems, RNAi pathway could be triggered by introducing 
expressing long dsRNA. Once cleaved by cytoplasmic nuclease Dicer into 21–23 
bp small interfering RNAs (siRNAs), the dsRNA then unwind and assemble into 
RNA-induced silencing complexes (RISCs). The antisense siRNA strand then 
guides the RISC to complementary RNA molecules, and the RISC cleaves the 
























Fig. 24 Transfection efficiency 
In the optimized condition, Random sequence siRNAs (the negative control) 
conjugated with Cy3 and oligofectamine were used to transfect BV-2 cells in the 
normal procedure. After 12-hour transfection, the supernatant was removed from 
the cells and the cells were washed with PBS vigorously. Cy3 labeling was found 
in all the BV-2 cells transfected using Oligofectamine (A-C), while no such 
staining was found in the cells without Oligofectamine treatment (D-F). 
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6.1.2 Decrease in expression of CD11b mRNA after siRNA transfection 
After optimizing all the transfection conditions, including the amount of 
transfection reagent, amount of the siRNA and number of the cells, Real-time 
PCR analysis showed that there was more than 80% decrease in expression of CD 
11b mRNA in BV-2 cells 48 and 72 hours after transfection, the decrease declined 
to only 42% at 96 hours after transfection (Fig. 25). As shown by 
immunocytochemistry, the CD11b protein expression level were clearly decreased 











Fig. 25 Decrease of CD11b mRNA expression in BV-2 cells after siRNA 
transfection 
BV-2 cells were incubated with the transfection complex (Oligofectamine and 
CD11b siRNA) for 12 hours before adding DMEM containing 30% FBS. 
Real-Time PCR showed that CD11b mRNA expression was significantly decreased 
in BV-2 cells transfected with CD11b siRNA. (**p<0.001) 
 














Fig. 26 Decrease of CD11b protein expression in BV-2 cells after siRNA 
transfection 
 
CD11b siRNA transfected (B and D) and the control (A and C) cells were 
immunocytochemically stained with anti-CD11b at 72 (A and B) and 96 (C and D) 






RESULTS                                                        105
6.1.3 No toxic effect of the transfection on BV-2 cells 
There was no obvious alteration in BV-2 cell viability at 48 and 96 hours 
after transfection (Fig. 27), indicating that the transfection process has no toxicity 










Fig. 27 Cell Viability after transfection 
Viabilities of CD11b siRNA transfected BV-2 and the control cells were measured 
by MTS test. The result shows there was no obvious cell viability change at 48 or 
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6.2 Alterations in microglial functions after CD11b siRNA 
6.2.1 Inhitition of LPS-induced upregulation of CD11b expression 
 The intensity of CD11b staining was stronger in negative control BV2 cells 
(Fig. 28C) in comparison to normal BV2 cells (Fig. 28A). The weakest CD11b 
staining was in CD11b siRNA cells (Fig. 28E). 24 hours after 1µg/ml LPS 
stimulation, both of normal (Fig. 28B) and the negative control BV-2 (Fig. 28D) 
cells showed up-regulation in expression of CD11b. However, this increase was 































Fig. 28 CD11b upregualtion sitmulated by LPS 
The CD11b knockdown BV-2 (E, F) and negative control (C, D), and normal (A, 
B) cells were incubated with LPS for 24 hours (B, D, F). Then Cy3 conjugated 
anti-CD11b was used to stain the cells to evaluate CD11b expression upon 
LPS-induced microglial activation. While upregulation in CD11b expression could 
be observed in negative control (D) or normal BV-2 cells (B), the increase of 
CD11b immunostaining intensity was significantly attenuated in CD11b 
knockdown cells (F). after LPS stimulation, suggesting an inhibition of microglial 
response to LPS stimulation. Scale bar, 100 μm. 
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6.2.2 Inhibition in cell migration 
To determine the effect of CD11b siRNA transfection on cell migration 
and gap closure, an in vitro gap closure model was employed in the present study. 
The gap was achieved by horizontal scraping across the bottoms of wells 
containing 90% confluent BV-2 cells (Guo et al., 2003).The rate of gap closure 
was determined by measuring the distance of the gap at 0, 12 and 24 hours after 
scraping. Then the ratio of gap width after scraping to original gap width were 
compared among normal BV-2, the negative control and the CD11b siRNA 
transfected BV-2 cells. The rate of gap closure was slower in both of the negative 
control and the CD11b siRNA transfected BV-2 cells. Although there was no 
obvious difference in the gap closure rate between the negative control and the 
CD11b siRNA transfected BV-2 cells at 12 hours post-scraping, a significant 
slower rate was observed in the CD11b siRNA transfected group at 24 hours 
post-scraping, in comparison with that in the negative control group (Fig. 29 and 



















Fig. 29 Migration  
BV-2 (A-C), negative control (D-F) and CD11b siRNA transfected BV-2 (G-I) 
cells were grown in six-well plates until they achieved 90% confluence. Using the 
tip of a 100μl plastic pipette, 3 horizontal lines were scraped across the bottom of 
each well. The gaps were measured at 0 (A, D, G), 12 (B, E, H) and 24 (C, F, I) 

















Fig. 30 Migration 
The distance between the edges of the gap was determined at 0, 12 and 24 hours 
after scraping, as a measure of cell migration. Cell migration abilities were 
compared among the groups by using the ratio of gap closure calculated between 
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6.2.3 Inhibition in phagocytotic function 
 For analysis of microglial phagocytotic activity, latex beads were applied to 
BV-2 cells. The results showed that only a small percentage of unstimulated BV-2 
cells ingested latex beads. The number of phagocytotic cells increased 
significantly 24 hours after LPS stimulation, while this increase was obviously 













Fig. 31 Phagocytosis  
Three days after transfection, CD11b siRNA transfected BV2 and the control cells 
were stimulated with LPS for 24 hours before 2-hour incubation with latex beads.  
(A) BV-2 cells; (B) LPS stimulated BV-2 cells; (C) LPS stimulated CD11b siRNA 
transfected cells; (D) LPS stimulated negative control cells. Scale bar: 50 μm. 
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Fig. 32 Statistic analysis of beads intake  
Phagocytosis was compared by counting the number of injested latex beads 
between the CD11b siRNA transfected BV-2 and the control cells. Phagocytosis of 
BV-2 cells induced by LPS was obviously inhibited after CD11b siRNA 
transfection. (*p<0.05; **<0.001) 
 
6.2.4 Inhibition in NO generation 
Previous study using DAF-2DA fluorescence to monitor NO production 
and the results has shown that there was no NO production at 12 hours but a 
marked increase of the fluorescence was observed at 24 hours after the cells were 
treated with 1µg/ml LPS (He et al., 2002). So in the present study, the time 
interval for observation of NO generation was set up at 24 hours after LPS 
stimulation. At 24 hours after 1µg/ml LPS stimulation, both of normal BV-2 and 
the negative control showed dramatic up-regulation in expression of CD11b and 
generation of intracellular NO. However, these marked increases were 
significantly attenuated in the CD11b siRNA transfected BV-2 cells (Fig. 33 and 
Fig. 34). 
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Fig. 33 NO generation 
Intracellular NO was measured by DAF-2DA fluorescence (excitation wavelength 
at 470–490 nm and emission wavelength at 515 nm) in BV-2 (A), CD11b 
knockdown BV-2(B) and negative control (C) cells without LPS stimulation. After 
24-hour LPS treatment, the NO expressions were evaluated again by DAF-2DA in 
BV-2 (D), CD11b knockdown BV-2 (E), and Negative control (F). DAF-2DA 
fluorescence results showed that the up-regulation of intracellular NO generation 
upon LPS stimulation was inhibited in CD11b siRNA transfected BV-2 cells. All 


















Fig. 34 Double labeling of NO (Green) and CD11b (Red)  
After 24-hour stimulation with LPS, intracellular NO was measured by DAF-2DA 
fluorescence and CD11b by Cy3 conjugated anti-CD11b immunostaining. More 
double labeled cells were observed in LPS-stimulated BV-2 (B) or negative 
control (D) cells in comparison that of unstimulated BV-2 (A) or LPS stimulated 
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6.2.5 Inhibition in expressions of cytokines 
Activated microglia produce various pro-inflammatory (such as TNF-α, 
IL-1β, and IL-6) and anti-inflammatory (such as IL-10 and TGF-β1, but not IL-4) 
cytokines (Aloisi, 2001; Munch et al., 2003). However, at high concentration of 
LPS, conditioned medium from microglia caused neuronal cell death in a 
dose-dependent manner (Block and Hong, 2005; Li et al., 2007) . The cytotoxicity 
of microglia is mainly mediated by NO and several pro-inlammatory cytokines 
secreted from the activated cells (Lee et al., 1992; Banati et al., 1993; Mogi et al., 
1994; Qin et al., 2002; Dheen et al., 2005). In the present study, there was no 
mRNA expression of IL-4 detected in LPS stimulated CD11b knockdown BV-2 
and the control cells, confirming that activated microglia may not be a source of 
IL-4. As very little mRNA expressions of IL-10 and TGF-β1 were detected, there 
was no obvious increase of the mRNAs observed in CD11b knockdown BV-2 and 
the control cells in response to high concentration of LPS (1 μg/ml). Real-time 
PCR analysis showed that mRNA levels of iNOS, TNFα, IL-6 and IL-1β were 
significantly increased in BV-2 and negative control cells upon LPS stimulation. 
This was further confirmed by Westerm blot results, which showed obvious 
increases in protein levels of iNOS, TNFα, IL-6 and IL-1β in the negative control 
and normal BV-2 cells after LPS stimulation. However, such significant increases 
were markedly inhibited in the CD11b siRNA transfected BV-2 cells at mRNA 
(Fig. 35) and protein level (Fig. 36 and 37), suggesting that the CD11b siRNA 
transfection has an inhibitive effect on the generation of those cytokines and iNOS 
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Fig 35 Cytokine mRNA expressions 
72 hours after siRNA transfection, the CD11b knockdown and the control cells 
were stimulated with LPS for 24 hours. The mRNA expressions of iNOS (A), 
TNF-α (B), IL-1β (C) and IL-6 (D) were detected by Real-time PCR. The 
LPS-induced upregulation in expressions of those cytokines was significantly 






















Fig 36 Cytokine protein expressions 
72 hours after siRNA transfection, the CD11b knockdown and the control cells 
were stimualated with LPS for 24 hours, the protein expressions of TNF-α, iNOS, 































Fig. 37 Statistic analysis of Western blot of cytokine proteins. 
The ratio of the  intensity of bands of TNF-α (A), iNOS (B), Il-1β(C) and IL-6 (D) 
to that of Actin were used to analyze protein expression levels of those cytokines 
between siRNA transfected and the control cells after 24-hour stimulation with 
LPS. The increases in protein expression levels of the cytokines in normal BV-2 
and negative control cells were significantly inhibited in the CD11b knockdown 
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6.2.6 Inhibition in LPS-induced microglial cytotoxity 
A standard curve (Figure. 38) was prepared for MTS test to analyze the 
cytotoxity of CD11b knockdown and the control cells. Compared to supernatant 
derived from unstimulated BV-2 cells, LPS-activated supernatant from the CD11b 
knockdown and all the control groups induced a similar degree of loss of NSC-34 
neuron viability after 24-hour exposure as there was no significant difference in 
the decrease of the viabilities among those groups. However, 48 hours after 
administration of the LPS-activated BV-2 supernatant, further decrease in the 
NSC-34 neuron viability was observed in all the groups but not in the group with 
conditioned medium from CD11b knockdown BV-2 cells (Fig. 39), suggesting a 




















Fig. 38 Effect of cell number on absorbance at 490nm measured using the 
CellTiter 96 ® AQueous Assay 
2.5, 5, 10, 20, 40, 80 ×103 cells were seeded in 96-well plate. The medium was 
allowed to equilibrate for 1 hour, then 20µl/well of combined MTS/PMS solution 
were added. After 1 hour at 37°C in a humidified, 5% CO2 atmosphere, the 
absorbance at 490nm was recorded using an ELISA plate reader. Each point 
represents the mean ± SD of 4 replicates. The correlation coefficient of the line 


























Fig. 39 Cell viability of NSC-34 neurons 
LPS was used to treat the CD11b knockdown BV-2 and the control cells for 24 
hours. The conditioned medium collected was applied to NSC-34 neurons at 
various concentrations. The viabilities of the NSC-34 cells were detected after 24 
and 48 hour treatment by MTS test. At 48 hours after treatment, the conditioned 
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7. Effect of CD11b siRNA transfection on MAPK signaling pathway in BV-2 
cells stimulated by LPS 
MAPKs are among the most important molecules in the signaling 
pathways that control the synthesis and release of proinflammatory substances by 
activated microglia (Koistinaho and Koistinaho, 2002). The possibility was raised 
that CD11b knockdown inhibited LPS-induced proinflammatory cytokines by 
downregulating MAPKs. In the present study, LPS-induced activation of ERK, 
JNK and P38 in normal BV-2, the negative control and CD11b siRNA transfected 
BV-2 cells were examined. All the three groups of cells were treated with 1µg/ml 
LPS for 10, 30 and 60 minutes before protein extraction.  
As shown by the protein level of phosphorylated ERK in Fig. 40 and Fig. 
41, ERK was significantly activated as early as 10 minutes in normal BV-2 cells 
after LPS treatment, but this marked upregulation of phosphorylated ERK 
diminished afterwards from 30 to 60 minutes. In the negative control, ERK 
activation increased gradually from 10 to 60 minutes after LPS stimulation. 
However, in the CD11b siRNA transfeced cells, there was no increase of ERK 
activation observed. The results suggested an inhibitive effect of the CD11b 
siRNA transfection on LPS-induced ERK activation in BV-2 cells. Certain amount 
of phosphorylated ERK protein was found in both of the negative control and 
CD11b siRNA transfeced cells before LPS stimulation, in comparison with that in 
the normal BV-2 cells. This may be due to the transfection complex which might 
induce such a small amount of ERK activation. 






Fig. 40 Activation of ERK1/2 Mapkinase pathway in CD11b knockdown BV-2 
cells treated with LPS 
All the three groups, BV-2, Negative Control and CD11b knockdown cells were 
incubated with LPS (1μg/ml) for 10, 30, and 60 minutes and then ERK1/2 MAPKs 
and its phosphorylated forms were detected by Western blotting from total cell 
lysates. The activation of ERK1/2 MAPKs in BV-2 cells peaked at 10 minutes after 
LPS stimulation. The peak has been delayed at least till 60 minutes after LPS 
treatment in the negative control cells. However, the peak of ERK1/2 activation 








Fig. 41 Activation of ERK1/2 Mapkinase pathway in CD11b knockdown BV-2 
cells treated with LPST 
The ERK1/2 MAPKs and its phosphorylated forms were detected using Western 
blotting from total cell lysates from BV-2, Negative Control and CD11b 
knockdown cells after application of LPS (1μg/ml) for 10, 30, and 60 minutes. The 
quatitative data showed that knocked down CD11b could significantly inhibit 
activation of ERK1/2 MAPKs. (*P<0.05; **P<0.001) 
Pho-ERK 
ERK 
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An obvious upregulation of phosphorylated JNK was in normal BV-2 cells 
at 10 minutes, this increase continued to the peak at 30 minutes and then 
decreased to low level at 60 minutes after LPS stimulation. Activated JNK 
increased from 10 until 60 minutes which is the peak time point in the negative 
control group. Although there was a trend of increase of activated JNK as well in 
the CD11b siRNA transfeced cells, the intensity was markedly less than that in the 
other two groups (Fig. 42 and Fig. 43). The results suggested an inhibitive effect 
of the CD11b siRNA transfection on JNK activation in BV-2 cells. Some 
expressions of phosphorylated JNK protein were found in the negative control and 
CD11b siRNA transfeced cells, comparing to that in the normal BV-2 cells. This 
may be induced by the transfection complex in the transfection process. 
 
Fig. 42 Activation of JNK Mapkinase pathway in CD11b knockdown BV-2 
cells treated with LPS 
All the three groups, BV-2, Negative Control and CD11b knockdown cells were 
incubated with LPS (1μg/ml) for 10, 30, and 60 minutes and then JNK MAPKs 
and their phosphorylated forms were detected by Western blotting from total cell 
lysates. Upon LPS stimulation，increased JNK activation peaked at 30 minutes in 
BV-2 cells but at 60 minutes in negative control as well as CD11b siRNA 
transfected BV-2 cells. However, the increase was the least in the CD11b siRNA 














Fig. 43 Activation of JNK Mapkinase pathway in CD11b knockdown BV-2 
cells treated with LPS 
The JNK MAPKs and their phosphorylated forms from BV-2, Negative Control 
and CD11b knockdown cells were detected using Western blotting from total cell 
lysates after co-incubation with LPS (1μg/ml) for 10, 30, and 60 minutes. No 
significant activation in JNK was detected in BV-2 cells with CD11b siRNA 
transfection while significant increases reached the highest in normal BV-2 cells 
at 30 minutes and in negative control BV-2 cells at 60 minutes after LPS 
stimulation. (*P<0.05; **P<0.001) 
 
      Marked upregulation of phosphorylated P38 was found in normal BV-2 
cells at 10 and 30 minutes and then diminished at 60 minutes after LPS 
stimulation, while obvious increase of activated P38 was not observed in the 
negative control until 30 minutes and then lasted to 60 minutes. The marked 
expression of phosphorylated P38 was significantly inhibited in the CD11b siRNA 
transfected BV-2 cells (Fig. 44 and Fig. 45), suggesting an inhibitary effect of the 
CD11b siRNA transfection on P38 activation in BV-2 cells. 







Fig. 44 Activation of P38 Mapkinase pathway in CD11b knockdown BV-2 
cells treated with LPS 
All the three groups, BV-2, Negative Control and CD11b knockdown cells were 
incubated with LPS (1μg/ml) for 10, 30, and 60 minutes and then p38 MAPKs and 
their phosphorylated forms were detected by Western blotting from total cell 
lysates. After LPS stimulation, the increases in P38 activation peaked at 30 
minutes in normal and negative control BV-2 cells. While the increase remained at 
high level till 60 minutes in the negative control BV-2 cells, only slight signals 




















Fig. 45 Activation of P38 Mapkinase pathway in CD11b knockdown BV-2 
cells treated with LPS 
The quatitative results showed that significant upregulation in P38 activation was 
detected in normal and negative control BV-2 cells after the cells were treasted 
with LPS (1μg/ml) for 10, 30, and 60 minutes. In response to LPS, The increase in 
the amount of P38 phosphorylation reached the highest at 30 minutes in normal 
and negative control BV-2 cells. The increase remained at high level in the 
negative control BV-2 cell. But no significant increase in the P38 activation was 
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1. Neuropathology developed in the spinal cord at the early age of of NFL-/- 
mice 
1.1 NFL-/- mice could serve as neurodegerative disease model 
Intracellular or extracellular protein aggregates, massive neuron death and 
drastic microglial reaction are common features of most neurodegenerative 
diseases. Unfortunately, these features observed from post mortem autopsies 
mainly represent features at a late stage of the diseases. Although not a universal 
feature, a decreased expression in NFL has been reported in some cases of adult 
onset neurodegenerative diseases, especially in ALS (Wong et al., 2000; Menzies 
et al., 2002) and normal aging. Based on this premise, NFL-/- mice were 
employed as a neurodegenerative disease model to study the relationship between 
diseased motoneurons and surrounding glial cells. Three development stages of 
neurodegeneration have been clarified in this animal model. In the first stage, 
abnormal neurofilament accumulations form in the neuronal perikarya and 
proximal axons. In the second stage, microglial number increases but the number 
of aggregate-bearing neurons begins to decline. In the last stage, motoneuron 
numbers decrease with a significant increase in numbers of astrocytes (McLean et 
al., 2005). In the present study, the research was mainly focused on the first stage, 
which is before the significant motoneuron death, to further explore the 
relationship between the diseased motoneurons and microglial reactions in the 
lumbar cord segments of NFL-/- mice. At this point, it is of importance to note 
that the Rota-Rod test showed that there was no obvious motor dysfunction in the 
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early age of NFL-/- mice. 
1.2 Protein aggregates detected in motoneurons of the lumbar cord segments 
of NFL-/- mice 
Abnormal protein aggregate is one of the common features of most 
neurodegenerative diseases. The targeted disruption of the NFL gene has 
confirmed the importance of NFL in intermediate filament assembly in neurons. 
In the absence of NFL, NFM and NFH would not be able to assemble into 10 nm 
filaments (Julien, 1999). In concert with previous studies (Zhu et al., 1997; 
McLean et al., 2005), striking protein aggregates of NFH and NFM were detected 
in cell bodies and axons of motoneurons in the lumbar cord segments in the 
NFL-/- mice. However, only NFH (not NFM) immunostaining was markedly 
decreased in axons in the ventrolateral region of the cord of NFL-/- mice, 
suggesting that a differential mechanism may be involved in the transport of 
different neurofilament subunits. These aggregates have been found to be able to 
sequester a number of cytoskeletal proteins and enzymes, including intermediate 
filaments, ubiquitin, nitric oxide synthase (NOS) and its metabolic by-products, 
SOD-1, and a variety of oxidative markers (Manetto et al., 1988; Leigh et al., 
1989; Corbo and Hays, 1992; Migheli et al., 1993; Abe et al., 1995; Chou et al., 
1996; Zhu et al., 1997; Sanelli et al., 2004; McLean et al., 2005), suggesting that 
NF aggregates could clearly precede the onset of motor dysfunction and consistent 
with having a primary role in the disease processes (Wang et al., 2002). 
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1.3 Further evidence for neuropathogenesis the spinal cord in early age of 
NFL-/- mice:  Neuronal degeneration, less numbers of motoneuron and 
decrease in size of the spinal cord 
Although mild neurological dysfunctions have been confirmed in the tests 
for balance and equilibrium in a group of 5~7 month old NFL-/- mice in a recent 
report (Dubois et al., 2005), no obvious motor dysfunction was detected using the 
Roto-Rod in the early age of the NFL-/- mice. However, motoneurons in the 
ventral horn of the NFL-/- spinal cord presented degenerating morphology have 
been detected using silver staining. In addition, a 20% reduction in the number of 
large neurons in the ventral horn of the lumbar cord segments was observed in 
NFL-/- mice from ages of 1 to 6 months. The less numbers of motoneurons and 
the decrease in the size of the spinal cord in the NFL-/- mice may be due to 
retardation in fetal development as the result of NFL disruption. Before the age of 
6 months, the NFL-/- mice showed neurodegeneration without obvious further 
loss of neurons in the spinal cord. 
2. No glial activation detected in the spinal cord at the early age of NFL-/- 
mice 
 The upregulation in expression of CD11b and GFAP serve as early indicators 
for activation of microglia and astrocytes (Gehrmann et al., 1995; Eng et al., 
2000). In the present study, no upregulation of CD11b expression, no increase in 
the number of microglia, no obvious migration of microglia towards 
protein-aggregate neurons have been observed in the spinal cord of NFL-/- mice. 
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There was no upregulation in expression of GFAP in astrocytes and no 
hypertrophy of astrocytes in the spinal cord of NFL-/- mice. It appears that the 
degenerating protein-aggregate containing neurons in the spinal cord of NFL-/- 
mice may not send out signal(s) to activate surrounding non-neuronal cells at the 
early stage of neuropathogensis.  
 It is possible that the interruption of NFL expression in the mice might cause 
microglia as well as astrocytes in lossing their ability to respond against 
neurodegeneration. However, microglia and astrocytes could still swiftly become 
activated in the spinal cord of NFL-/- mice after sciatic nerve transection, 
indicating that microglia and astrocytes in the NFL-/- mice still possess the ability 
to react to neurodegeneration. Whether the degenerating neurons at early stage 
could release any signal to glial cells should be a key issue in the early 
development of neurodegenerative diseases. 
3. Downregulation in expression of CD11b detected in the spinal cord at the 
early age of NFL-/- mice: an inhibitory niche?  
 Suprisingly, a significant downregulation in expression of CD11b in microglia 
in the ventral horn of the lumbar cord segment in the NFL-/- mice at the early age 
was detected by immunohistochemical staining and confirmed at mRNA level by 
Real-Time PCR. This downregulation in CD11b expression was the strongest in 
young NFL-/- mice at 1 month of age but become reduced afterwards. In NFL-/- 
mice, CD11b mRNA expression has recovered to 80 percent of that in the age 
matched C57BL/6 mice at the 6-month time point.  
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It is again not unreasonable to assume that normal microglial function 
would be compromised as a direct result of the disruption of NFL gene in NFL-/- 
mice. However, no detectable difference in CD11b expression in peripheral 
macrophages from the liver and spleen between NFL-/- and C57BL/6 mice was 
observed, suggesting that the targeted disruption of NFL gene would not directly 
affect the down-regulation of CD11b expression in the cells with monocytic 
features. The down-regulation of CD11b expression in microglia suggests that 
certain factor(s), which would suppress microglial CD11b expression and the 
resultant microglial reaction, may exist in the microenvironment with the protein 
aggregate-bearing motoneurons in the NFL-/- mice.  
The question is therefore raised on whether an inhibitory niche would exist 
in the early development stage of neurodegenerative diseases. It is therefore of 
importance to know if downregulation of CD11b could indicate the inhibition of 
microglial function. 
4. Further evidence support a selective downregulation of microglial 
functions in the spinal cord at the early age of NFL-/- mice 
4.1. Delayed transformation of microglia in response to axotomy in NFL-/- 
mice 
 After sciatic nerve transection, a sign of delayed morphological 
transformation from ramified to amoeboid microglia in the lumbar cord of the 
NFL-/- mice may have provided another evidence for the existence of the assumed 
inhibitory factor(s). However, microglia in NFL-/- mice displayed a swift reaction 
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to sciatic nerve transection which was similar to that in C57BL/6 control mice. 
Apparent proliferation and migration of microglia were also observed in the 
ipsilateral dorsal and ventral horns of the lumbar cord segments in both types of 
mice after nerve transection. These suggested that the effects of the signal(s) 
generated from axotomized motoneurons may overall surpass the effects of the 
inhibitory signal(s) from protein-aggregate containing motoneurons. 
4.2 Induced Iba-1 expression in CD11b positive cells 
 A previous study has observed a significant increase in the number of Iba-1 
positive microglia since the age of 4 months (McLean et al., 2005), however, there 
was no obvious change in the number of CD 11b positive microglia in the NFL-/- 
mice at that time. Although it remains unclear if the down-regulation of CD 11b 
expression would eventually lead to inhibition of microglial function in this case, 
the induction of molecule Iba-1 expression in some CD 11b positive microglia 
after sciatic nerve injury have clearly suggested the alteration in microglial 
functions. While there was a down-regulation of CR3 α-subunit expression in 
microglia in NFL-/- mice till 6 month old, CD11b mRNA expression has 
recovered to 80 percent of that in the age matched C57BL/6 mice at 6-months of 
age. At the same time, the expression of Iba-1 has been induced in some CD11b 
positive microglia which may eventually result in the significant increase in the 
number of Iba-1 positive microglia observed since the age of 4 months in the 
previous report (McLean et al., 2005), implying a possible alteration in microglial 
functions at the early age of NFL-/- mice.  
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4.3 Differential expressions in some cytokines 
As cytokines are key regulators of innate and adaptive immune responses 
in both disease conditions and experimental studies and microglia are the principal 
source of cytokines in the CNS (Aloisi, 2001), some cytokine mRNA expressions 
in the spinal cord were further evaluated. In the present study, differential 
expressions in cytokines in the lumbar cord segments of NFL-/- mice were 
observed: There was no alteration in TGF-β1, IL-10 and TNF-α expressions but 
an increase in IL-1β and a decrease in IL-4 mRNA expression have been observed 
in the NFL-/- mice.  
5. The possible role of the inhibitory niche to microglia in early 
neuropathogenesis of neurodegenerative diseases  
Although it is still required to further confirm whether this differential 
expression of cytokines and surface receptors/molecules in the cells in the lumbar 
cord segments of NFL-/- mice would function as toxic or protective factors to the 
protein aggregate-bearing neurons, it is safe to say that the niche in the spinal cord 
of NFL-/- mice is different from that of the normal control and the niche is also 
different between earlier and later stages of pathological development in the spinal 
cord of NFL-/- mice. 
The down-regulation in CD 11b in earlier ages of the NFL-/- mice, a rather 
unexpected feature, is contrary to the clinical feature of significant microglial as 
well as astrocytic reactions in late stage of neurodegenerative diseases (McGeer 
and McGeer, 1998). In the animal model with permanent middle cerebral artery 
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occlusion, the Mac-1 (CD11b/18) monoclonal antibody was administrated at 1 
hour after the occlusion and a decrease in the number of necrotic neurons could be 
observed 12 hours after the occlusion (Garcia et al., 1996). The inhibition of 
resident microglial and/or blood-derived monocyte activation by the 
administration of anti-Mac-1 has also been reported to lead to a significant 
reduction in the severity of ibotenate-induced brain lesions as well as in 
ibotenate-induced cortical apoptotic reaction (Dommergues et al., 2003). 
Activated microglia may potentiate the excitotoxicity that contributes to neuronal 
death and dysfunction (Dommergues et al., 2003; McCarty, 2006). It is worth to 
note from previous studies that motoneurons in the NFL-/- spinal cord were under 
stress indicated by up-regulation of heat shock protein-70 in the motoneurons at 
the first stage (Dommergues et al., 2003; McLean et al., 2005). Together with the 
fact that the aggregate-bearing motoneuron death does not happen until the second 
stage, it might suggest a protective role contributed by microglia with inhibition of 
CD 11b expression in the survival of abnormal protein aggregate-bearing 
motoneurons at an early stage of the pathogenesis of neurodegeneration in the 
NFL-/- mice. This might be a possible feature in pre-clinical development of 
neurodegenerative diseases. 
However, the role of CD11b in determination of microglial function 
should be further addressed in order to understand more on this possible 
pre-clinical phenomenon. 
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6. Role of CD11b in the inhibitory niche 
6.1 Establishment of CD11b knockdown model in vitro 
Drastic microglial reaction with high CD11b expression is one of the 
common features of many neurodegenerative diseases. However, in early stage of 
neurodegeneration development in NFL-/- mice, a motoneuron diseased mouse 
model, there was no obvious evidence of miroglial activation surrounding the 
aggregates bearing motoneurons. Instead, a downregulation of CD11b expression 
was observed in microglia in the mice. Together with the fact that there was no 
cell death of the aggregate-bearing motoneurons until a later stage, it is concluded 
that this inhibition of CD11b might serve a protective role in the survival of the 
diseased motoneurons (Li et al., 2006). To further clarify the cause or effect 
relationship between downregulation of CD11b expression and inhibition of 
microglial activation, siRNA transfection has been induced to knockdown the 
CD11b gene in BV-2 microglial cells. 
Gene silencing using double-stranded siRNA is widely used to examine 
functions of a candidate gene in a range of normal physiologic and pathologic 
processes. This technology, which causes the specific degradation of mRNA with 
sequences homologous to the introduced duplexes, has been applied to many 
genes and cell types, but has not been previously applied to the gene of CD11b. 
Through simple modifications to a common lipid mediated transfection procedure, 
CD 11b siRNA have been successfully transfected into BV-2 microglial cells to 
knockdown the expression of CD11b. In the optimized condition, the transfection 
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resulted in a strongly reduced CD11b mRNA expression but did not alter the 
viability of the cells. This has prodived a model to explore the effect of 
downregulation of CD11b expression in microglia and the possible cellular 
mechanisms involved.  
The CR3 (CD11b/CD18) was originally identified as a LPS receptor 
(Wright and Jong, 1986), but subsequent studies performed on monocytes and 
macrophages derived from CD18-deficient patients led to the conclusion that 
CD18 is not essential for cellular responses to LPS (Wright et al., 1990). 
Therefore, the present study has focused only on the CD11b subunit of CR3. 
6.2 CD11b knockdown could result in slower microglial migration 
It has been well known that CD11b has critical role in the migration ability 
of microglia. In the current research, an obvious slower migrating rate was 
observed in the CD11b knockdown BV-2 microglial cells, indicating that 
microglial migration ability was weakened by inhibiting CD11b expression using 
siRNA. The findings have not only confirmed the important role of CD11b in the 
migration ability of microglia, but also suggested a possible way of inhibiting 
CD11b to delay or control microglial migration to damaged areas which may lead 
to further damages in neurodegenerative diseases.  
6.3 CD11b knockdown could decrease phagocytotic function of microglia 
Microglia upregulate their phagocytic function when they become 
activated. As reviewed by (Smith, 2001), microglia have been shown to engulf 
many substances, including latex beads, bacteria, fluorescent labeled liposomes, 
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IgG-coated erythrocytes, zymosan, oxidized LDL, α2 macro-globulin, as well as 
myelin vesicles, both untreated and opsonized.  
CR3 has been widely reported as a professional phagocytic receptor of 
microglia and mediates type Ⅱ phagocytosis by binding C3bi-opsonized targets 
(Caron and Hall, 1998). This type of phagocytosis occurs through sinking of the 
C3bi-coated particle into the cell, generating little or no membrane protrusion, and 
a less tightly apposed phagosomal membrane (Allen and Aderem, 1996; Kaplan, 
1977). 
The upregulation of phagocytic function of BV-2 due to LPS has been well 
documented (Smith et al., 1998), the present study showed an obvious increase in 
the number of beads engulfed by BV-2 and the negative control cells after 24-hour 
stimulation with LPS. But this increase was significantly inhibited in CD11b 
knockdown microglial cells, confirming that CD11b is an important receptor for 
phagocytic activity of microglia and also suggesting that the downregulation of in 
expression of CD11b in NFL-/- mice may result in an inhibition in microglial 
phagocytotic activity.  
When co-cultured with astrocytes (Lee et al., 1992) or incubated with 
astrocytes-conditioned medium (Suzumura et al., 1990), ameboid microglia have 
been shown to downregulate their phagocytic function (Smith and Hoerner, 2000) 
and change back to their ramified morphology. This suggests that the phagocytic 
function of microglia can be modulated by external factors in its environment, 
supporting the notion that the degenerating neurons at early stage in the NFL-/- 
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mice could release signal(s) to inhibiti microglia. Cytokines are among the factors 
that can affect the phagocytic function of microglia. When microglia become 
activated, they can release pro-inflammatory cytokines like TNF-α, Il-6 and IL-1β. 
The expression of cytokines elevated in MS lesions (Cannella and Raine, 1995) 
has been shown to double the phagocytic activity of microglia. Administration of 
a specific iNOS inhibitor also abolished macrophage phagocytic activity, hence 
demonstrating that NO produced by macrophages has a role not only in 
intracellular killing but also in phagocytic activity (Tumer et al., 2007).  
This implies that microglial phagocytosis could not only be affected by 
CD11b directly but also be modulated by factors released from microglia or other 
cells.  
6.4 CD11b knockdown could result in differential expressions of cytokines 
Inflammation is a response of the organism to injury related to physical or 
chemical noxious stimuli or microbiological substances, which is involved in 
multiple neurodegenerative diseases, including AD, PD, Huntington's disease, MS, 
and ALS (Wilms et al., 2007). Microglia, as the resident innate immune cells in 
the brain, actively monitor their environment and can become over-activated in 
response to diverse cues to produce cytotoxic factors, such as superoxide (Colton 
and Gilbert, 1987), NO (Liu et al., 2002; Moss and Bates, 2001), IL-1β and 
TNF-α (Lee et al., 1993; Sawada et al., 1989). While microglial activation is 
necessary and critical for host defense, over-activation of microglia is neurotoxic 
(McGeer et al., 2005; Polazzi and Contestabile, 2002). Therefore, it is important 
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and reasonable to study the effect of CD11b knockdown on cytokines generated 
by activated microglial cells. In the present study, protein levels of IL-1β, IL-6 and 
TNF-α were markedly increased in normal BV-2 and the negative control cells in 
response to LPS stimulation. However, these increases were significantly inhibited 
in the CD11b knockdown microglial cells, suggesting that CD11b could be an 
important receptor for cytokine generations in LPS-activated microglial cells. The 
downregulation of this receptor may lead to an effective inhibition of microglial 
activities in cytokine generation. 
6.5 CD11b knockdown could result in decrease in NO generation  
There are 3 types of NOS, endothelium, neuronal and inducible NOS. 
iNOS is a high output isoform compared to the other two which are constitutively 
expressed NOS. iNOS from murine macrophages is induced at the transcriptional 
level by LPS, but can also be regulated post-transcriptionally (Xie and Nathan, 
1994). 
Microglia have also been associated with chronic inflammation which is 
responsible for neuronal death seen in neurological diseases like PD, where there 
is a loss of dopaminergic neurons (McGeer and McGeer, 2004). Activated 
microglia has been shown to upregulate the expression of iNOS, with 
immunohistochemistry for iNOS protein demonstrating selective localization in 
microglia only (Possel et al., 2000). Microglia activated by LPS have been shown 
to mediate neuronal cell injury by producing NO, a neurocytotoxic free radical 
(Chao et al., 1992), while microglia-mediated cell death was inhibited when iNOS 
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inhibitors were used (Gibbons and Dragunow, 2006). 
LPS is capable of eliciting drastic NO generation and increasing 
phagocytosis of microglia. In the present study, the remarkable increases of those 
two activities were significantly inhibited in BV-2 cells after the knockdown of 
CD11b gene. This inhibitive effect on NO generation was confirmed in the level 
of iNOS expression (Real-time PCR and Western blot) and NO generation 
(DAF-2DA fluorescence) in vitro. The results suggest that CD11b knockdown can 
inhibit NO generation in microglia in response to LPS stimulation, which might 
further downregulate the phagocytic activities of the cells and turned down 
microglial cytotoxicity. 
6.6 CD11b knockdown could attenuate neurotoxicity of LPS-stimulated 
microglia  
Microglial activation is a reactive process and microglia may respond to 
signals arising from injured neurons. In many types of neuropathology, activated 
microglia are always limited spatially to those regions occupied by injured 
neurons and their processes. This suggests an important interactive relationship 
between activated microglia and injured neuronal cells in these diseases. 
There is growing evidence that activated microglia are involved in many 
neurodegnenerative diseases (Brown, 2001; Dickson et al., 1993; Raine, 1994). 
Besides morphological changes and surface molecule upregulation, activated 
microglia secrete a host of soluble factors. The majority of factors such as TNF-α 
and IL-1β are produced by activated microglia. However, they are 
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proinflammatory and neurotoxic (Liu and Hong, 2003). Studies using cell culture 
and animal models have demonstrated that excessive quantities of individual 
factors produced by activated microglia can be deleterious to neurons (Boje and 
Arora, 1992; Chao et al., 1992; McGuire et al., 2001). Furthermore, individual 
factors often work in concert to induce neurodegeneration. For example, it has 
been reported that the combination of IL-1β and TNF-α, but not either cytokine 
alone, induced the degeneration of cortical neurons (Chao et al., 1995). Jeohn and 
colleagues have shown that the combination of IL-1β, TNF-α and interferon-γ 
work in synergy to induce degeneration of cortical neurons (Jeohn et al., 1998).  
The medium from LPS stimulated BV-2 cells has been demonstrated to be 
toxic to neuronal cells (Li et al., 2007). In the present study, the author found that 
upregulation of iNOS, IL-1β, Il-6 and TNF-α protein expressions were inhibited in 
the CD11b knockdown microglial cells in response to LPS stimulation, comparing 
with thoese of the control cells. It is then reasonable to assume that the toxicity of 
activated microglia may also be attenuated after knocking down the gene of 
CD11b in the cells. The NSC-34 cells were exposed separately to 70%, 80%, 90% 
and 100% of conditioned medium from high dose of LPS (1μg/ml) stimulated 
CD11b knockdown and the control BV-2 cells for 24 and 48 hours. The viability 
was significantly higher in neurons treated with conditioned medium from CD11b 
knockdown microglia than in the other control groups at the 48 time point. This 
suggests that downregulation of CD11b could not only suppress microglial 
activities in NO generation and cytokine secretions, but also attenuate the toxicity 
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of LPS-stimulated microglia to neurons. This downregulation of CD11b 
expression may play a protective role to neuronal cells and represent a practical 
strategy for combating neurodegenerative disorders by inhibiting micrglial 
acitivities. 
7. The signal(s) to trigger the downregulation in expression of CD11b is still 
unknown 
In the case of a reversible injury, such as motoneuron axotomy, the nature 
of signals from injured neurons might induce generation of neurotrophic factors 
from perineuronal microglia or other glial cells. In the case of an irreversible 
injury, such as acute intoxication or ischemic damage, neuron-derived signals 
might cause microglia to release neurotoxic factors, which could quickly ‘finish 
off' the non-viable cells. This would facilitate removal of degenerating debris via 
phagocytosis by the perfectly positioned perineuronal microglial cells.  
Since the ensheathment of injured neurons by activated microglial cells 
could be viewed as preparation for imminent phagocytosis, there may be a fine 
line between the generation of survival-promoting and death-promoting signals. 
Thus, the different types of neuronal signals, as well as the ensuing microglial 
responses, must be highly specific. This reciprocal specificity could be facilitated 
to a large extent by the close proximity between neurons and microglia, allowing 
these interactions to occur only between the juxtapositioned cells. Therefore, the 
bioactive factors released by both neurons and microglia could be effective at very 
low concentrations. Close apposition between microglia and neurons is a common 
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occurrence in the normal CNS (Palacios, 1990), but it becomes particularly 
conspicuous during reactive microgliosis when neurons are often surrounded by 
several activated microglial cells (Kreutzberg, 1966; Barron et al., 1990; Graeber 
and Mehraein, 1994; Streit and Sparks, 1997). But the signaling mechanism 
between them is still a mistery. To identify those signals is beyond the scopes of 
the present study due to the limitations of time and techniques. However, some 
downstream components in signaling pathways, which may be involved in CD11b 
activation, were investigated in the present study, hoping this could provide some 
hints for understanding the signaling mechanism between neurons and microglia. 
8. MAPKinase pathway involved in CD11b mediated microglial functions 
 LPS has been well known to activate a series of MAPKs such as ERK, p38 
and JNK in immune cells (DeFranco et al., 1995; Guha and Mackman, 2001), 
which have especially been implicated in the signal transduction pathways 
responsible for increased iNOS, IL-1β, IL-6 and TNF-α gene expressions in glial 
cells (Da et al., 1997; Xu and Malave, 2000; Pawate and Bhat, 2006). Three major 
subfamilies of MAPK cascades, i.e., ras-raf1-MEK1/2-ERK1/2, 
rac-MEKK1-MEK4/7-JNK1/2 and MEK3/6-p38 MAPK, have been defined 
(Krens et al., 2006). MAPKs transmit signals in the form of sequential 
phosphorylation events. The dual-phosphorylation of a conserved domain (TXY) 
of MAPKs by the upstream MEK1/2, MEK3/6 and MEK4/7 leads to activation of 
ERK, p38 MAPK and JNK, respectively (Krens et al., 2006). The three 
MAPKinases differ in their responses to extracellular stimuli. ERKs are most 
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responsive to growth factors and phorbol esters (Cobb and Goldsmith, 1995), 
whereas JNK and p38 MAP kinase are activated in response to stress signals, 
including UV irradiation, heat, osmotic stress, LPS, and proinflammatory 
cytokines such as IL-1β, IL-6, and TNF-α (Kyriakis et al., 1994; Raingeaud et al., 
1995).  
 Thus, the role of CD11b in the cellular mechanism of LPS induced signal 
transduction was further evaluated in microglial cells by Western blots. The results 
show that significant activations of ERK, P38 and JNK were induced in normal 
BV-2 and the negative control cells, while such increases were strongly inhibited 
by knockdown of CD11b. These findings suggest that downregulation of CD11b 
is indeed capable of disrupting the key signal transduction pathways elicited by 
LPS in BV2 cells, and subsequently preventing the production of proinflammatory 
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Adult onset neurodegenerative diseases are the main causes for disability, 
dementia, and death in elderly people. Intracellular or extracellular protein 
aggregates, massive neuron death, and drastic microglial reaction are common 
features of most neurodegenerative diseases. Unfortunately, these features 
observed from post-mortem autopsies mainly represent features at a late stage of 
the diseases, and the knowledge on early pathogenesis, which is more important 
for diagnosis and treatment of the diseases, is still significantly insufficient. 
Although not a universal feature, a decreased expression in NFL has been reported 
in some cases of adult onset neurodegenerative diseases, especially in ALS 
(Menzies et al., 2002; Wong et al., 2000) and normal aging. Based on this premise, 
the present study used NFL−/− mice as a neurodegenerative disease model to 
examine the relationship between diseased motoneurons and surrounding glial 
cells. Three development stages of neurodegeneration have been clarified in this 
animal model. In the first stage, abnormal neurofilament accumulations form in 
the neuronal perikarya and proximal axons. In the second stage, microglial 
number increases but the number of aggregate-bearing neurons begins to decline. 
In the last stage, motoneuron number decreases with a significant increase in the 
number of astrocytes (McLean et al., 2005).  
The present study, which mainly focuses on the first stage, shows a series 
of neurodegenerative features including abnormal protein aggregates of NFH and 
NFM in the neuronal cell bodies and processes, less motoneuron cell number and 
smaller size of the spinal cord in NFL-/- mice. However, there were no noticeable 
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changes in motor function, numbers of microglia GFAP staining of astrocytes. 
Unexpectedly, a downregulation in expression of CD11b, α subunit of CR3, was 
detected in the spinal cord of NFL−/− mice, while there was no obvious difference 
in the CD11b staining intensity in macrophages from the liver and spleen between 
NFL−/− and C57BL/6 mice. In addition, retardation in morphological 
transformation from activated to amoeboid microglia in response to sciatic nerve 
injury, differential expressions of some cytokines in the lumbar cord segments and 
induction of Iba-1 expression in microglia were observed in NFL−/− mice, 
pointing to an inhibitory niche for microglia in the spinal cord at the early age of 
NFL-/- mice 
To clarify the relationship between the downregulation of CD11b and 
inhibition of microglial activities observed in the NFL-/- mice, the present study 
has employed the transient siRNA transfection approach to specifically 
knockdown CD11b gene expression in BV-2 microglial cells and explored the role 
of CD11b in microglial activities and the cellular signalling mechanism induced 
by LPS. After successfully knocking down the CD11b gene in BV-2 cells, the 
present study discovers that this specific CD11b downregualtion may not only 
slow down cell migration rate, but also inhibit the increases in phagocytosis, 
intracellular NO generation and cytokine expressions in BV-2 cells upon LPS 
stimulation. In addition, the CD11b knockdown also inhibit activations of the 
MAPKinase pathway including phosphorylation of ERK, JNK and P38, which are 
among the most important molecules in the signaling pathways that control the 
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synthesis and release of proinflammatory substances by activated microglia 
(Koistinaho and Koistinaho, 2002). The present study also demonstrates that the 
conditioned medium from LPS-simulated CD11b knockdown BV-2 cells was 
found less toxic to NSC-34 neurons than that from the control cells. 
Chronic neurodegenerative disorders are characterized by activation of 
microglia in the affected regions. Biofactors generated by the activated microglia 
can potentiate the excitotoxicity that contributes to neuronal death and dysfunction 
in these disorders by direct or indirect effects on neurons. The possible therapeutic 
interventions which could down-regulate microglial activation in the early stage of 
neuropathogenesis may have a favorable effect on preventing further progression 
of neurodegenerative diseases. The results of the present study not only shed more 
lights on the understanding of neuropathogenesis at earlier stage of 
neurodegenerative diseases and provide fundamental bases for earlier diagnosis 
and treatment, but also reveal that inhibition of CD11b by siRNA may reduce 
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